var title_f20_19_20784="Metaphyseal fracture of the proximal humerus";
var content_f20_19_20784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metaphyseal fracture of the proximal humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Healing undisplaced fracture of the proximal humerus in a 5-year-old child. Note the absence of a physeal injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20784=[""].join("\n");
var outline_f20_19_20784=null;
var title_f20_19_20785="Pipemidic acid: International drug information";
var content_f20_19_20785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pipemidic acid: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Balurol (BR);",
"     </li>",
"     <li>",
"      Biosoviran (IT);",
"     </li>",
"     <li>",
"      Cistomid (IT);",
"     </li>",
"     <li>",
"      Deblaston (AT, DE, ZA);",
"     </li>",
"     <li>",
"      Diperpen (IT);",
"     </li>",
"     <li>",
"      Dolcol (JP);",
"     </li>",
"     <li>",
"      Elofuran (BR);",
"     </li>",
"     <li>",
"      Faremid (IT);",
"     </li>",
"     <li>",
"      Finuret (AR);",
"     </li>",
"     <li>",
"      Galusan (ES);",
"     </li>",
"     <li>",
"      Memento (AR);",
"     </li>",
"     <li>",
"      Nuril (ES);",
"     </li>",
"     <li>",
"      Palin (RU);",
"     </li>",
"     <li>",
"      Pimidel (RU);",
"     </li>",
"     <li>",
"      Pipeacid (IT);",
"     </li>",
"     <li>",
"      Pipedac (IT);",
"     </li>",
"     <li>",
"      Pipefort (IT);",
"     </li>",
"     <li>",
"      Pipemid (IT);",
"     </li>",
"     <li>",
"      Pipram (BR, FR, IT, NL);",
"     </li>",
"     <li>",
"      Pipurin (IT);",
"     </li>",
"     <li>",
"      Pipurol (BR);",
"     </li>",
"     <li>",
"      Priper (AR);",
"     </li>",
"     <li>",
"      Purid (CL);",
"     </li>",
"     <li>",
"      Septidron (ZA);",
"     </li>",
"     <li>",
"      Uribac (MX);",
"     </li>",
"     <li>",
"      Uriken (MX);",
"     </li>",
"     <li>",
"      Uripiser (MX);",
"     </li>",
"     <li>",
"      Urisan (ES);",
"     </li>",
"     <li>",
"      Urixin (MY);",
"     </li>",
"     <li>",
"      Uroden (IT);",
"     </li>",
"     <li>",
"      Uronovag (MX);",
"     </li>",
"     <li>",
"      Uropimide (CL, IT);",
"     </li>",
"     <li>",
"      Uropipedil (ES);",
"     </li>",
"     <li>",
"      Uropipemid (MX);",
"     </li>",
"     <li>",
"      Urosan (IT);",
"     </li>",
"     <li>",
"      Urosetic (IT);",
"     </li>",
"     <li>",
"      Urotractin (HK, IT, MY, SG, TH);",
"     </li>",
"     <li>",
"      Uroxina (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F3335319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Pipemidic Acid Trihydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3335320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimicrobial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3335321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute, chronic, and recurrent urinary tract infections (cystitis, urethritis, prostatitis, pyleonephritis) by sensitive organisms such as",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     , and",
"     <i>",
"      Citrobacter",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3335323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Usual dose: 400 mg twice daily after meals; maximum duration of treatment: 10 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3335324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10498 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-97C5FA2E12-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20785=[""].join("\n");
var outline_f20_19_20785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302645\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335319\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335320\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335321\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335323\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821138\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335324\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20786="Calculator: Serum osmolal gap (SI units)";
var content_f20_19_20786=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"OsmolalGap_SI_form\" name=\"OsmolalGap_SI_form\" onkeydown=\"clrResults();\" onkeyup=\"OsmolalGap_SI_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Serum osmolal gap (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          CalculatedOsm = (SerumNa * 2) + SerumGlucose + SerumBUN  + (SerumEthanol * 1.25)",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          OsmolalGap = MeasuredOsm - CalculatedOsm",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Na_param\" onblur=\"OsmolalGap_SI_fx(); minMaxCheck();\" onchange=\"OsmolalGap_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Na_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Glucose",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Glucose_param\" onblur=\"OsmolalGap_SI_fx(); minMaxCheck();\" onchange=\"OsmolalGap_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Glucose_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum BUN",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_BUN_param\" onblur=\"OsmolalGap_SI_fx(); minMaxCheck();\" onchange=\"OsmolalGap_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_BUN_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Ethanol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Ethanol_param\" onblur=\"OsmolalGap_SI_fx(); minMaxCheck();\" onchange=\"OsmolalGap_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Ethanol_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Measured Osm",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Measured_Osm_param\" onblur=\"OsmolalGap_SI_fx(); minMaxCheck();\" onchange=\"OsmolalGap_SI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Measured_Osm_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|mOsm/dL\">",
"               mOsm/dL",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mOsm/kg\">",
"               mOsm/kg",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Calculated Osm",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Calculated_Osm_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Calculated_Osm_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"               <option value=\"10|0|mOsm/dL\">",
"                mOsm/dL",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mOsm/kg\">",
"                mOsm/kg",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Osmolal Gap",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Osmolal_Gap_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Osmolal_Gap_unit\" onchange=\"OsmolalGap_SI_fx();\" style=\"width:105px;\">",
"               <option value=\"10|0|mOsm/dL\">",
"                mOsm/dL",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|mOsm/kg\">",
"                mOsm/kg",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"OsmolalGap_SI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      The plasma osmolality is determined by the concentration of the different solutes in the plasma.",
"In normal subjects, sodium salts (chloride and bicarbonate), glucose, and urea are the primary",
"circulating solutes. The calculated plasma osmolality normally is between",
"270 and 290 mOsm/kg H2O and the",
"      <b>",
"       Osmolal Gap",
"      </b>",
"      is normally  &lt;10 mOsm/kg H2O. You can calculate the",
"      <b>",
"       Osmolal Gap",
"      </b>",
"      from the formulas depicted.",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Bhagat CI, Garcia-Webb P, Fletcher E, et. al. Calculated vs measured plasma osmolalities revisited.",
"        <i>",
"         Clin Chem",
"        </i>",
"        . 1984 Oct;30(10):1703-5.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Purssell RA, Pudek M, Brubacher J, et. al. Derivation and validation of a formula to calculate the  contribution of ethanol to the osmolal gap.",
"        <i>",
"         Ann Emerg Med",
"        </i>",
"        . 2001; 38:653.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20786=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function OsmolalGap_SI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.OsmolalGap_SI_form){",
"",
"",
"doCalc = true;",
"if (Serum_Na_param.value.indexOf(',') >= 0){ Serum_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Na_unit.options[Serum_Na_unit.selectedIndex].value.split('|');",
"Serum_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Glucose_param.value.indexOf(',') >= 0){ Serum_Glucose_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Glucose_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Glucose_unit.options[Serum_Glucose_unit.selectedIndex].value.split('|');",
"Serum_Glucose = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_BUN_param.value.indexOf(',') >= 0){ Serum_BUN_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_BUN_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_BUN_unit.options[Serum_BUN_unit.selectedIndex].value.split('|');",
"Serum_BUN = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Ethanol_param.value.indexOf(',') >= 0){ Serum_Ethanol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Ethanol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Ethanol_unit.options[Serum_Ethanol_unit.selectedIndex].value.split('|');",
"Serum_Ethanol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Measured_Osm_param.value.indexOf(',') >= 0){ Measured_Osm_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Measured_Osm_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Measured_Osm_unit.options[Measured_Osm_unit.selectedIndex].value.split('|');",
"Measured_Osm = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Calculated_Osm =  (Serum_Na * 2) + Serum_Glucose + Serum_BUN  + (Serum_Ethanol * 1.25);",
"",
"unit_parts = Calculated_Osm_unit.options[Calculated_Osm_unit.selectedIndex].value.split('|');",
"if (doCalc) Calculated_Osm_param.value = fixDP((Calculated_Osm - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"Osmolal_Gap =  Measured_Osm - Calculated_Osm;",
"",
"unit_parts = Osmolal_Gap_unit.options[Osmolal_Gap_unit.selectedIndex].value.split('|');",
"if (doCalc) Osmolal_Gap_param.value = fixDP((Osmolal_Gap - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.OsmolalGap_SI_form){",
"",
"if (Serum_Na_param.value && Serum_Na < 50) {",
"Serum_Na = 0;",
"Serum_Na_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum Na is 50 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Na_param.value && Serum_Na > 200) {",
"Serum_Na_param.value = \"\";",
"clrResults();",
"Serum_Na = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum Na is 200 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Glucose_param.value && Serum_Glucose < 0) {",
"Serum_Glucose = 0;",
"Serum_Glucose_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum Glucose is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Glucose_param.value && Serum_Glucose > 83) {",
"Serum_Glucose_param.value = \"\";",
"clrResults();",
"Serum_Glucose = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum Glucose is 83 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_BUN_param.value && Serum_BUN < 0) {",
"Serum_BUN = 0;",
"Serum_BUN_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum BUN is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_BUN_param.value && Serum_BUN > 54) {",
"Serum_BUN_param.value = \"\";",
"clrResults();",
"Serum_BUN = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum BUN is 54 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Ethanol_param.value && Serum_Ethanol < 0) {",
"Serum_Ethanol = 0;",
"Serum_Ethanol_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum Ethanol is 0 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Ethanol_param.value && Serum_Ethanol > 435) {",
"Serum_Ethanol_param.value = \"\";",
"clrResults();",
"Serum_Ethanol = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum Ethanol is 435 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.OsmolalGap_SI_form){",
"",
"Calculated_Osm_param.value = '';",
"Osmolal_Gap_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f20_19_20786=null;
var title_f20_19_20787="Open globe laceration with a teardrop pupil";
var content_f20_19_20787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open globe laceration with a teardrop pupil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture demonstrating a globe laceration and teardrop pupil.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hoff AM Stead LG, Smith VD. Traumatic globe laceration. J Trauma 2010; 68:746. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20787=[""].join("\n");
var outline_f20_19_20787=null;
var title_f20_19_20788="Onchochorioretinitis";
var content_f20_19_20788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Onchochorioretinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Onchocercal chorioretinits with optic disc pallor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murdoch ME, Murdoch IE. Onchocerciasis. In: Principles of Medicine in Africa, 3rd Ed, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press 2004. Copyright &copy; 2004 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20788=[""].join("\n");
var outline_f20_19_20788=null;
var title_f20_19_20789="Nelarabine: Pediatric drug information";
var content_f20_19_20789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nelarabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"    see \"Nelarabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/12/12485?source=see_link\">",
"    see \"Nelarabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arranon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5505580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atriance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4288457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F4288467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=see_link\">",
"      see \"Nelarabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols: I.V.:",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     T-cell ALL, T-cell lymphoblastic lymphoma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 650 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1 through 5; repeat cycle every 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1, 3, and 5; repeat cycle every 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For neurologic toxicity &ge; grade 2 of NCI Common Toxicity Criteria: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     For hematologic or other non-neurologic toxicity: Consider treatment delay",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No adjustment recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Data are insufficient for a dosing recommendation; monitor closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Safety has not been established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bilirubin &gt;3 times ULN: Monitor closely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1988006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arranon&reg;: 5 mg/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1987963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4288468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: The appropriate nelarabine dose is transferred into an empty polyvinyl chloride infusion bag or glass container and administered undiluted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Infuse over 1 hour daily for 5 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Infuse over 2 hours on days 1, 3, and 5",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4288464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials at room temperature. Undiluted injection solution is stable in a polyvinyl chloride infusion bag or glass container for up to 8 hours at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4288458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma [FDA approved in pediatrics (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;\">",
"       Nelarabine may be confused with clofarabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2115652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Chest pain, edema, hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Amnesia, aphasia, ataxia, attention disturbance, balance disorder, cerebral hemorrhage, coma, confusion, depressed level of consciousness, depression, dizziness, encephalopathy, fatigue, fever, headache, hemiparesis, hydrocephalus, hypoesthesia, insomnia, intracranial hemorrhage, lethargy, leukoencephalopathy, loss of consciousness, mental impairment, motor dysfunction, nerve paralysis, neuropathic pain, nerve palsy, pain, seizure, paralysis, sciatica, sensory disturbance, sensory loss, somnolence, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Petechiae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Dehydration, hyper-/hypoglycemia, hypocalcemia,hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, anorexia, constipation, diarrhea, nausea, stomatitis, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, neutropenic fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Albumin decreased, AST increased, bilirubin increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthralgia, back pain, dysarthria, hypertonia, hyporeflexia, incoordination, limb pain, muscle weakness, myalgia, noncardiac chest pain, paresthesia, peripheral neuropathy, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, dyspnea, epistaxis, pleural effusion, pneumonia, sinus headache, sinusitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Craniospinal demyelination, neuropathy (peripheral) (similar to Guillain-Barr&eacute; syndrome), opportunistic infection, pneumothorax, progressive multifocal leukoencephalopathy (PML), respiratory arrest, rhabdomyolysis, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4288460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nelarabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4288828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone marrow suppression, including leukopenia, thrombocytopenia, anemia, neutropenia, and febrile neutropenia are associated with treatment; monitor blood counts regularly. Use extreme caution in patients with elevated uric acid, gout, and history of uric acid stones (monitor for hyperuricemia, consider allopurinol, and hydrate accordingly). Use caution in patients with renal impairment and severe hepatic impairment. Avoid administration of live vaccines in immunocompromised patients on nelarabine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4288461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Severe neurotoxicity, including severe somnolence, seizure, and peripheral neuropathy, has been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Observe closely for signs and symptoms of neurotoxicity; discontinue if &ge;grade 2. Adverse effects associated with demyelination or similar to Guillain-Barr&eacute; syndrome (ascending peripheral neuropathies) have also been reported. Neurologic toxicities may not fully resolve and neurologic function return to baseline after treatment cessation. Neurologic toxicity is dose-limiting. Risk of neurotoxicity may increase in patients with concurrent or previous intrathecal chemotherapy or history of craniospinal irradiation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1987980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentostatin: May diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1987969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1987970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4288469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for neurologic toxicity (severe somnolence, seizure, peripheral neuropathy, confusion, ataxia, paresthesia, hypoesthesia, coma, or craniospinal demyelination); signs and symptoms of tumor lysis syndrome; hydration status; CBC with platelet counts, renal and liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4288465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nelarabine is a prodrug that is demethylated by adenosine deaminase to ara-G. Ara-G is phosphorylated by deoxyguanosine kinase and deoxycytidine kinase to ara-GTP (active). Ara-GTP is incorporated into the DNA of leukemic blasts leading to inhibition of DNA synthesis and cell death. Ara-GTP appears to accumulate at higher levels in T-cells compared with B-cells correlating to its differential activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4288466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Nelarabine: Adults: 197 &plusmn; 216 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Children: 213 &plusmn; 358 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ara-G: Adults: 50 &plusmn; 24 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Children: 33 &plusmn; 9.3 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Nelarabine and ara-G: &lt;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Nelarabine is O-demethylated to ara-G by adenosine deaminase; ara-G undergoes hydrolysis to guanine; guanine is N-deaminated to xanthine which is further oxidized to form uric acid and then oxidized to form allantoin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nelarabine: 13 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ara-G: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nelarabine: 18 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ara-G: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Nelarabine 6.6% and ara-G 27% are excreted in urine within 24 hours of infusion on day 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Nelarabine clearance is ~30% higher in children (259 &plusmn; 409  L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     ) than in adults (197 &plusmn; 189 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     ); ara-G clearance in children (11.3 &plusmn; 4.2 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     ) is similar to adults (10.5 &plusmn; 4.5 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F4288470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/12/12485?source=see_link\">",
"      see \"Nelarabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Notify physician if unusual bleeding, bruising, breathing difficulty, somnolence, confusion, seizures, coma, peripheral neuropathy (numbness and tingling in the hands, fingers, feet, or toes), problems with fine motor skills, unsteady gait, weakness, or paralysis occurs. Women of childbearing potential should be advised to avoid becoming pregnant while receiving nelarabine treatment.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berg SL, Blaney SM, Devidas M, et al, &ldquo;Phase II Study of Nelarabine (Compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children&rsquo;s Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3376-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20789/abstract-text/15908649/pubmed\" id=\"15908649\" target=\"_blank\">",
"        15908649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gandhi V, Plunkett W, Weller S, et al, \"Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(8):2142-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20789/abstract-text/11304766/pubmed\" id=\"11304766\" target=\"_blank\">",
"        11304766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kurtzberg J, Ernst TJ, Keating MJ, et al, \"Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3396-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20789/abstract-text/15908652/pubmed\" id=\"15908652\" target=\"_blank\">",
"        15908652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12993 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20789=[""].join("\n");
var outline_f20_19_20789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709168\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987961\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5505580\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288457\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288467\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987963\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288468\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288464\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288458\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401809\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2115652\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288460\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288828\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288461\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299749\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987980\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987969\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987970\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288469\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288465\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288466\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4288470\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/45/21206?source=related_link\">",
"      Nelarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/12/12485?source=related_link\">",
"      Nelarabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20790="Recurrent bc postmastectomy";
var content_f20_19_20790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recurrent breast cancer in post mastectomy patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 582px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CC and MLO views (Panels A and B) of a TRAM flap in a woman with a palpable lump. An irregular nodule with spiculated margins is seen in the lower inner quadrant of the reconstructed breast, corresponding to the palpable lump marked on the skin with a BB marker. Ultrasound (Panel C) shows a solid nodule at the area of clinical lump. The ill defined and angulated margins on ultrasound correspond to the spiculations on mammogram.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal; MLO: mediolateral oblique; TRAM: transverse rectus abdominis myocutaneous.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20790=[""].join("\n");
var outline_f20_19_20790=null;
var title_f20_19_20791="Irbesartan and hydrochlorothiazide: Drug information";
var content_f20_19_20791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Irbesartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28229?source=see_link\">",
"    see \"Irbesartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avalide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avalide&reg;;",
"     </li>",
"     <li>",
"      CO Irbesartan HCT;",
"     </li>",
"     <li>",
"      Irbesartan-HCTZ;",
"     </li>",
"     <li>",
"      PMS-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      Ran&trade;-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      ratio-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      Sandoz-Irbesartan HCT;",
"     </li>",
"     <li>",
"      Teva-Irbesartan HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Maximum antihypertensive effects are attained within 2-4 weeks after initiation or a change in dose; however, if necessary, may carefully titrate dose as soon as after 1 week of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add-on therapy: A patient who is not controlled with either agent alone may be switched to the combination product. The lowest dosage available is irbesartan 150 mg/hydrochlorothiazide 12.5 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial therapy: Irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. If initial response is inadequate, may titrate dose after 1-2 weeks, to a maximum dose of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5583655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5583656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: 150/12.5: Irbesartan 150 mg and hydrochlorothiazide 12.5 mg; 300/12.5: Irbesartan 300 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avalide&reg; 150/12.5: Irbesartan 150 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avalide&reg; 300/12.5: Irbesartan 300 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avalide&reg; 300/25: Irbesartan 300 mg and hydrochlorothiazide 25 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy for the management of hypertension; may be used as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avalide&reg; may be confused with Avandia&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (3%), chest pain (2%), tachycardia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (8%; orthostatic: 1%), fatigue (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea/vomiting (3%), abdominal pain (2%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urination abnormal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased (2%), creatinine increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, hepatitis, hyperkalemia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation; sulfonamide-derived drugs; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with irbesartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use irbesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use irbesartan with caution with pre-existing renal insufficiency and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs. Combination product not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Irbesartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5583658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avalide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-12.5 mg (30): $123.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-12.5 mg (30): $134.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Irbesartan-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-12.5 mg (30): $111.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-12.5 mg (30): $121.43",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5583659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O reports daily to determine fluid loss; blood pressure, symptomatic hypotension, and tachycardia; serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aprozide (BR);",
"     </li>",
"     <li>",
"      Avalide (BZ, SR);",
"     </li>",
"     <li>",
"      Avapro HCT (AR, AU);",
"     </li>",
"     <li>",
"      Co-Aprovel (HK, MX, TH);",
"     </li>",
"     <li>",
"      Co-Irvebal (ID);",
"     </li>",
"     <li>",
"      CoApprovel (DE);",
"     </li>",
"     <li>",
"      Coaprovel (AR, AT, BB, BE, BG, BM, BS, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IT, JM, KP, MT, MY, NI, NL, NO, PA, PE, PH, PR, PT, PY, RU, SE, SG, SK, SV, TH, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Ibef (KP);",
"     </li>",
"     <li>",
"      Irbeprex H (CO);",
"     </li>",
"     <li>",
"      Irovel-H (IN);",
"     </li>",
"     <li>",
"      Irtan Plus (ID);",
"     </li>",
"     <li>",
"      Karvezide (AT, AU, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NO, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Oprestat (GT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Irbesartan:",
"     </b>",
"     Irbesartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Irbesartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrochlorothiazide:",
"     </b>",
"     Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5583653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, \"Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, \"Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neutel JM, Franklin SS, Oparil S, et al, &ldquo;Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as Initia Treatment for Rapid Control of Severe Hypertension,&rdquo;",
"      <i>",
"       J Clin Hypertens",
"      </i>",
"      , 2006, 8(12): 850-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/17170610/pubmed\" id=\"17170610\" target=\"_blank\">",
"        17170610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, \"Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/19/20791/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8990 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20791=[""].join("\n");
var outline_f20_19_20791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708953\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184390\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184391\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184407\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184394\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184395\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583655\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583656\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184370\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184383\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184411\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184405\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184385\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184373\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184401\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184377\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184378\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184387\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184397\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583658\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184386\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583659\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184388\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184372\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5583653\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28229?source=related_link\">",
"      Irbesartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20792="Anemia of prematurity";
var content_f20_19_20792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anemia of prematurity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20792/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/19/20792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoiesis decreases after birth as a result of increased tissue oxygenation due to the onset of breathing and closure of the ductus arteriosus, and a reduced production of erythropoietin (EPO) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/1\">",
"     1",
"    </a>",
"    ]. In term infants, the hemoglobin level typically reaches an average nadir of 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at approximately 8 to 12 weeks after birth.",
"   </p>",
"   <p>",
"    In preterm infants who are already born with a lower hematocrit, this decline referred to as anemia of prematurity (AOP) occurs earlier and is more pronounced in its severity than the anemia seen in term infants. The AOP will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cause of anemia of prematurity (AOP) is the impaired ability to increase serum erythropoietin (EPO) appropriately in the setting of anemia and decreased tissue availability of oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Circulating and bone marrow red cell progenitors respond to EPO, if present, indicating that the impaired erythropoiesis is due to lack of EPO, not a failure to respond to the hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Other hematopoietic growth factors (eg, granulocyte-macrophage colony-stimulating factor) are not affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impaired erythropoietin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPO is produced by the fetal liver and the cortical interstitial cells of the kidney in response to hypoxia. Its production is regulated by the transcription factor hypoxia inducible factor-1 (HIF-1). Its primary function is to regulate erythrocyte production. EPO does not cross the placenta in humans, and fetal production increases with gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Production of EPO in adults depends on the oxygen saturation of hemoglobin and tissue oxygen delivery, and is inversely proportional to central venous oxygenation. Although EPO levels in preterm infants with AOP increase slightly with hypoxia, they are lower than those seen in older children and adults with the same level of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In AOP, the specific mechanisms leading to the discrepancy between serum EPO concentration and the severity of the anemia are uncertain. Proposed pathogenetic pathways involve the site of EPO production and the developmental regulation of transcription factors in the liver versus the kidney.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The liver is the principal site of EPO production in the fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. The feedback increase in hepatic EPO mRNA in response to anemia, and hypoxia may be less than that of the kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/14\">",
"       14",
"      </a>",
"      ]. EPO mRNA expression in the kidney is present in the fetus, and increases significantly after 30 weeks gestation, suggesting that the switch to the kidney as the main site of EPO production is developmentally regulated.",
"     </li>",
"     <li>",
"      The fetal or neonatal environment may alter the response to hypoxic signals by the liver. Support for this hypothesis comes from the observation that hepatic transplantation from fetal and neonatal lambs into adult sheep increased EPO production by the transplanted liver [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transcriptional regulatory factors, such as HIF-1, may contribute to low levels of EPO in premature infants. These factors activate target genes, including those encoding EPO, in response to decreased cellular oxygen concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. They appear to be developmentally regulated in some fetal tissues, which might account for the decreased expression of EPO in response to anemia in preterm infants [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/1,18\">",
"       1,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although AOP is directly due to impaired EPO production, several other factors can contribute to anemia in preterm infants, including blood loss from phlebotomy, reduced red blood cell life span, and iron depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Blood loss from phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants frequently develop an early anemia that is primarily due to iatrogenic blood loss due to phlebotomy for blood tests. The volume of blood loss increases with illness severity and decreasing gestational age. In one report, withdrawal of blood in excess of that required for laboratory studies contributed to iatrogenic blood loss by 2 to 4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per week [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/19\">",
"     19",
"    </a>",
"    ]. However, efforts to reduce blood loss from phlebotomy have resulted in changes in clinical practice to limit blood sampling for essential testing and the use of microtechniques, which have reduced iatrogenic blood loss.",
"   </p>",
"   <p>",
"    The impact of clinical practice on phlebotomy and blood testing was illustrated in a study of very low birth weight (VLBW) infants (birth weight &lt;1500 g) cared for in two neonatal intensive care units (NICUs) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/20\">",
"     20",
"    </a>",
"    ]. Phlebotomy losses increased with decreasing gestational age and increasing illness severity, as measured by the Score for Neonatal Acute Physiology (SNAP). The average losses due to phlebotomy differed between the two NICUs and resulted in increased average blood transfusion requirements in the NICU with the greater volume of blood loss. However, this difference was not associated with differences in the days of oxygen therapy or mechanical ventilation, risk of bronchopulmonary dysplasia, or growth rate by day 28 of life. These findings suggest that the additional use of blood in one of the NICUs was discretionary rather than necessary, as clinical outcomes did not differ.",
"   </p>",
"   <p>",
"    These studies indicate that blood loss due to phlebotomy in preterm infants may be greater than is necessary for the care of the neonate. They emphasize the need for nursery policies to ensure that only the minimal volume required for testing is drawn, and unnecessary tests are avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Reduced red blood cell life span",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell survival in newborn term infants is approximately 60 to 80 days but decreases with decreasing gestational age to a range of 45 to 50 days in extremely low birth weight infants (ELBW) (birth weight below 1000 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/21\">",
"     21",
"    </a>",
"    ]. The reduced red cell life span contributes to the severity of anemia. Increased susceptibility to oxidant injury may contribute to shortened red cell survival in the neonate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Iron depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is not involved in its pathogenesis, iron depletion may impair recovery from AOP. Because of their rapid growth rate, premature infants have increased utilization and depletion of iron stores and, as noted above, blood loss from phlebotomy. The administration of iron does not inhibit the fall in hemoglobin concentration due to AOP. However, in term infants, it reduces the incidence of iron deficiency anemia in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low levels of other nutrients, such as vitamin B12 or folate, do not appear to contribute to neonatal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/1\">",
"     1",
"    </a>",
"    ]. In one randomized trial, the combination of folate, vitamin B12, iron, and EPO compared to control therapy improved the ELBW infant's chance of remaining transfusion free (38 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OXYGEN DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen delivery is the rate at which oxygen is transported from the lungs to the microcirculation. It is determined by the product of cardiac output and arterial oxygen content. The arterial oxygen content is the amount of oxygen bound to hemoglobin plus the amount of oxygen dissolved in arterial blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen delivery is dependent upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac output",
"     </li>",
"     <li>",
"      Hemoglobin concentration",
"     </li>",
"     <li>",
"      Oxygen carrying capacity (affinity) of hemoglobin",
"     </li>",
"     <li>",
"      Arterial oxygen saturation and oxygen tension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In preterm infants with anemia, physiologic changes, which aim at maintaining adequate oxygen delivery, compensate for a significant decrease in hemoglobin, and are similar to those seen in older children and adults. These include increases in heart rate and stroke volume, which improve cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, anemic preterm infants may be less able to maintain oxygen delivery because of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concomitant respiratory disease, such as respiratory distress syndrome and bronchopulmonary dysplasia, resulting in hypoxia.",
"     </li>",
"     <li>",
"      Limitations on maximum arterial oxygen saturation and oxygen tension for infants requiring respiratory support, because hyperoxia increases the risk of bronchopulmonary dysplasia and retinopathy of prematurity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Oxygen toxicity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H85370822#H85370822\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Supplemental oxygen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemoglobin F (HbF)-containing red cells in the premature infant have a considerably higher oxygen affinity than adult red blood cells, resulting in reduced delivery of oxygen to tissues (",
"      <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HbF binds poorly to 2,3 diphosphoglycerate (2,3-DPG), a potent modulator that diminishes the affinity of hemoglobin for oxygen. Decreased binding increases oxygen affinity and shifts the oxyhemoglobin dissociation curve to the left, resulting in decreased peripheral oxygen delivery (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proportion of HbF increases with decreasing gestational age, and is regulated developmentally so that HbF levels are similar at the same postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The concentration of HbF in an infant born at 28 weeks gestation is approximately 90 percent, and decreases to approximately 60 percent at 10 weeks after birth, a value that is similar to that of an infant newly born at 38 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia of prematurity (AOP) typically occurs at 3 to 12 weeks after birth in infants less than 32 weeks gestation. The onset of AOP is inversely proportional to the gestational age at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/1,29,30\">",
"     1,29,30",
"    </a>",
"    ]. The anemia typically resolves by three to six months of age.",
"   </p>",
"   <p>",
"    In a study of 40 very low birth weight (VLBW) infants, average hemoglobin concentrations fell from 18.2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at birth to a mean nadir of 9.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    at six weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/31\">",
"     31",
"    </a>",
"    ]. Values of 7 to 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    were common even in the absence of significant phlebotomy losses. Hematocrit values were lowest in the smallest infant with average nadirs of 21 percent in infants with birth weights (BW) less than 1000 g, and 24 percent in infants with BW between 1000 and 1500 g.",
"   </p>",
"   <p>",
"    Many infants are asymptomatic despite having hemoglobin values less than 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, other infants with AOP are symptomatic at similar or even higher hemoglobin levels because of a reduced capacity to maintain adequate oxygen by other means in compensation for AOP. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Oxygen delivery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Symptoms associated with AOP include tachycardia, poor weight gain, increased requirement of supplemental oxygen, or increased episodes of apnea or bradycardia. In a prospective study of preterm infants with birth weights less than 1500 g, the risk of apnea that lasted for more than 10 seconds rose with decreasing hematocrit values for both infants greater and less than 32 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, the frequency of apneic events detected by continuous monitoring of chest impedance and oxygen saturation decreased after red blood cell transfusion.",
"   </p>",
"   <p>",
"    The following laboratory findings in addition to anemia are characteristic of AOP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral blood smear demonstrates normocytic and normochromic red blood cells.",
"     </li>",
"     <li>",
"      The reticulocyte count is low, and red blood cell precursors in the bone marrow are decreased [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum concentrations of EPO are low in premature infants during the first postnatal month compared to adults (9.7 versus 15.2",
"      <span class=\"nowrap\">",
"       mU/mL)",
"      </span>",
"      and remain inappropriately low for the extent of anemia through the second postnatal month [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who care for premature infants should anticipate the development of anemia of prematurity (AOP). Optimal nutrition (eg, iron supplementation) should be provided and patients monitored for signs of anemia. Blood sampling should be limited to essential testing, and microtechniques should be used to minimize blood loss due to phlebotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Blood loss from phlebotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Red blood cell transfusions are primarily used to treat infants with AOP. Human erythropoietin (EPO) appears have limited benefit in decreasing exposure to different blood donors and is NOT recommended for routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Iron supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iron content at birth is lower in preterm infants than term infants, and the iron stores of preterm infants often are depleted by two to three months of age. As a result, all preterm infants who are breastfed should receive iron supplementation of 2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day through the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/36\">",
"     36",
"    </a>",
"    ]. Infants who receive iron-fortified formula need less additional supplementation than those who are exclusively breastfed, because for a given volume, iron-containing formula contains a higher concentration of iron than breast milk. Low iron containing preterm formulas should not be used as they do not adequately provide the necessary iron required for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although iron supplementation does not prevent AOP, the use of iron-fortified formula compared to nonfortified formula allows for greater iron substrate when erythropoiesis is stimulated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/37\">",
"     37",
"    </a>",
"    ]. Iron supplementation does reduce iron-deficiency anemia, which both premature and term infants are at high risk for developing in the first year of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematocrit (HCT) or hemoglobin (Hb) concentration should be monitored on a weekly basis in extremely low birth (ELBW) infants (birth weight less than 1000 g) in the first weeks of life. Thereafter, in healthy, growing premature infants, it is not necessary to routinely monitor",
"    <span class=\"nowrap\">",
"     HCT/Hb.",
"    </span>",
"    Infants with persistent illness (eg, bronchopulmonary dysplasia) or surgical issues may require monitoring.",
"   </p>",
"   <p>",
"    In asymptomatic infants, measuring a reticulocyte count at approximately four to six weeks after birth is used to evaluate whether a red blood cell (RBC) transfusion may be needed. Although no clearly defined biological markers have been identified to indicate when a RBC transfusion should be given in a premature infant, an absolute reticulocyte",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    (&lt;2 percent) is often used as a criterion for RBC transfusion in asymptomatic infants with a low HCT (less than 20 percent) or Hb (less than 7",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    The indications for neonatal RBC transfusion are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link\">",
"     \"Red blood cell transfusions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;RBC transfusion is the most rapidly effective treatment for AOP. However, transfusion is a temporary measure and has the disadvantages of further inhibiting erythropoiesis and being associated with risks of transmitted infection, graft-versus-host disease, and toxic effects of anticoagulants or preservatives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link\">",
"     \"Immunologic blood transfusion reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBC transfusion is performed when the level of anemia becomes symptomatic or is thought to compromise adequate oxygen delivery. Guidelines for RBC transfusion are based upon the patient's hematocrit (hemoglobin), their requirement for respiratory support, and the presence of symptoms consistent with anemia (eg, tachycardia, poor weight gain, increased requirement of supplemental oxygen, or increased episodes of apnea or bradycardia). The indications for transfusions, specific blood products available for transfusion, and the administration of transfusion in the neonate are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link\">",
"     \"Red blood cell transfusions in the newborn\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Oxygen delivery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenetic importance of impaired EPO production in AOP provides the rationale for the therapy with recombinant human EPO. However, this approach has not been accepted widely because it appears to have limited efficacy in decreasing the number of blood donors to which the infant is exposed via transfusion, whether EPO is administered early (within the first week of life) or late (at or after eight days of life). Data on the outcome of early and late EPO administration are presented in the following two sections.",
"   </p>",
"   <p>",
"    A more effective approach to reduce the number of donor exposures for the preterm infant than routine administration of EPO is to limit the amount of blood drawn, follow restrictive guidelines for red blood cell transfusion, and to use satellite packs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/38\">",
"     38",
"    </a>",
"    ]. Satellite packs involve dividing one unit of donor blood into multiple smaller aliquots, which allows repeated transfusions from the same donor to the individual infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H5#H5\">",
"     \"Red blood cell transfusions in the newborn\", section on 'Target hemoglobin or hematocrit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H15#H15\">",
"     \"Red blood cell transfusions in the newborn\", section on 'Administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In retrospective studies, early administration of EPO has been associated with an increased risk of retinopathy of prematurity (ROP). In addition, EPO is a costly intervention. As a result, the routine use of EPO in neonates is NOT recommended because the potential limited benefits are outweighed by the costs and possible risks of the intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Early EPO use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early administration (within the first eight days of life) of EPO appears to reduce the number of transfusions required in preterm infants, the small reduction may be of limited clinical importance, because EPO does not decrease the number of donor exposures due to the use of satellite packs. In addition, some trials suggest that early EPO administration increased the risk of retinopathy of prematurity (ROP).",
"   </p>",
"   <p>",
"    These findings were best illustrated in a meta-analysis of 23 trials (2074 preterm infants) that evaluated the effect of early administration of EPO (given before eight days of age) compared to placebo or no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/39\">",
"     39",
"    </a>",
"    ]. Many of these infants had received blood transfusions prior to enrollment in the trials. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 18 trials of 1825 infants, EPO reduced the risk of receiving one or more red blood cell transfusions (RR 0.80, 95% CI 0.75-0.86).",
"     </li>",
"     <li>",
"      In 13 trials of 1115 infants, EPO slightly reduced the number of red blood cell transfusions (weighted mean difference of -0.27, 95% CI -0.42 to -0.12).",
"     </li>",
"     <li>",
"      In 10 trials of 1425 infants, EPO increased the risk of ROP (RR 1.18, 95% 0.99-1.40). In a sub-analysis of 6 trials of 930 infants in which information was available, EPO appeared to increase the risk of severe ROP, defined as stage 3 or greater (RR 1.71, 95% CI 1.15-2.54).",
"     </li>",
"     <li>",
"      There were no differences between the EPO and placebo groups in the rates of mortality, sepsis, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), hypertension, length of hospital stay, or long-term neurodevelopmental outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, a review of the literature in 2012 did not identify any new studies to be included in the analysis.",
"   </p>",
"   <p>",
"    In a follow-up study from one of the trials included in the meta-analysis, EPO and placebo-treated infants at 18 to 22 months corrected age with birth weights &lt;1000 g had similar weight and length, number of rehospitalizations, transfusions after discharge, and developmental outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, early EPO is associated with only a small reduction in the number of transfusions, but no reduction in exposure to the number of donors, and has no impact on clinical outcomes.",
"   </p>",
"   <p>",
"    Although the meta-analysis also demonstrated a trend for an increased risk of ROP, this could be a chance finding because development of ROP was one of many secondary outcomes evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, the subanalysis that reported early administration resulted in an increased risk of severe ROP must be interpreted with caution, given that the overall effect on all grades of ROP was substantially lower. Among the studies included in the analysis, there were no data regarding the gestational age of the patients and illness severity, which both directly impact on the risk of ROP. Further studies are required to demonstrate whether or not there is a clinically significant association between early EPO use and ROP.",
"   </p>",
"   <p>",
"    Although it is difficult to determine the role of EPO in the multifactorial pathogenesis of ROP, the current evidence is sufficient to raise concerns about the early use of EPO given the limited benefit of reducing exposure to blood donors, its cost, and potential association with ROP. As a result, we recommend NOT to routinely administer EPO within the first eight days of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Late EPO use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late administration of EPO reduces the number of transfusions, but the limited benefit does not justify its use. This was illustrated in a meta-analysis of 28 trials (1361 preterm infants), which was updated in 2012, that evaluated the effects of late EPO administration (at or later than eight days of age) compared to placebo or no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/41\">",
"     41",
"    </a>",
"    ]. Most of these infants had received blood transfusions prior to enrollment in the trials. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EPO reduced the risk of receiving one or more red blood cell transfusions (RR 0.66, 95% CI 0.59-0.74).",
"     </li>",
"     <li>",
"      EPO reduced the number of red blood cell transfusions (weighted mean difference of -0.78, 95% CI -0.97 to -0.59).",
"     </li>",
"     <li>",
"      EPO had no effect on the rates for ROP, mortality, sepsis, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), hypertension, length of hospital stay, or long-term neurodevelopmental outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late administration of EPO reduced the mean number of transfusions by a little less than one transfusion per infant. This small benefit of EPO was diminished due to the exposure of previous blood transfusions before eight days of life, and the use of satellite packs that would mitigate against additional donor exposure in the control group. As a result, we recommend NOT to routinely administer EPO after eight days because its limited benefit of limiting exposure to blood donors does not justify its cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197405534\">",
"    <span class=\"h3\">",
"     Comparison early versus late use",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be no benefit of early EPO administration compared with late administration in reducing the number of transfusions, the amount of red cells transfused, or number of donor exposures per infant. This was illustrated in a meta-analysis of two trials (262 patients), which was updated in 2012, that found no statistical benefit of early EPO administration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. However, there appeared to be an increased risk of ROP associated with early administration. These data support the recommendation of not administrating EPO in the first eight days of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of EPO in premature infants appears to be safe. Hypertension, rash, bone pain, seizures, or later development of anti-EPO antibodies have not been reported in premature infants. Complications include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A transient neutropenia that resolves with cessation of therapy is occasionally observed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. In one trial, mean absolute neutrophil counts after 20 days were lower in premature infants who received EPO compared to red blood cell transfusion (1.8 x 10(3) versus 3.9 x 10(3)) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron deficiency occurs if supplementation is inadequate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/45-47\">",
"       45-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As discussed above, early administration of EPO has been associated with increased risk of ROP. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Early EPO use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;If EPO is given, it can be administered intravenously (200",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per dose once daily) or subcutaneously (400",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per dose, 3 times per week) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/48\">",
"     48",
"    </a>",
"    ]. When given intravenously, EPO should be mixed in a protein-containing solution (5 percent albumin) and given over at least four hours, or, more commonly, is added to TPN and administered daily over 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/49\">",
"     49",
"    </a>",
"    ]. The undiluted drug (2000",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    can be given subcutaneously in a volume of 0.2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for infants less than 1000 g. EPO preparation with higher concentrations (up to 10,000",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    can be used as the infant grows.",
"   </p>",
"   <p>",
"    In a small clinical trial, preterm infants who received 1200",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once a week and control infants who received the standard three times a week dosing (400",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    had similar increases in absolute reticulocyte counts and hematocrits at the end of the four-week trial period [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/50\">",
"     50",
"    </a>",
"    ]. However, further studies are needed to confirm that weekly dosing provides the same benefit as more frequent administration.",
"   </p>",
"   <p>",
"    Infants treated with EPO require iron supplementation. A proposed regimen is a daily elemental iron dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for infants on full enteral feedings, and 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for those taking at least 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/48\">",
"     48",
"    </a>",
"    ]. For infants receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/20/9542?source=see_link\">",
"     iron dextran",
"    </a>",
"    can be added to the solution (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reticulocyte count, central hematocrit or hemoglobin concentration, and absolute neutrophil count are measured before as well as one to two weeks after starting EPO treatment. EPO is withheld if the absolute neutrophil count is less than",
"    <span class=\"nowrap\">",
"     1000/microL.",
"    </span>",
"    Serum ferritin levels may be useful in evaluating those infants who are not responding to therapy to detect iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20792/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborn infants have a fall in hematocrit soon after birth due primarily to impaired production of erythropoietin. In preterm infants, the decline occurs earlier, is more pronounced, and is called anemia of prematurity (AOP). AOP typically occurs at 3 to 12 weeks after birth in infants less than 32 weeks gestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other contributors to anemia in the preterm infant include iron depletion, blood loss due to phlebotomy, and a reduced red blood cell life span in preterm infants compared to that of full term infants and adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preterm infants are at particular risk for impaired oxygen delivery with anemia because of the increased likelihood of concomitant respiratory disease, high levels of hemoglobin F, and the need to avoid hyperoxia, which increases the risk of BPD and retinopathy of prematurity (ROP). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Oxygen delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many infants remain asymptomatic despite having hemoglobin levels below 7",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      However, other infants may be symptomatic at similar or even higher hemoglobin levels. Symptoms include tachycardia, poor weight gain, increased requirement of supplemental oxygen, or increased frequency of apnea or bradycardia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical and laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory findings characteristic of AOP include normocytic and normochromic red blood cells, low reticulocyte count, and low erythropoietin levels. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical and laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AOP may require treatment with RBCs transfusion. However, transfusion is a temporary measure and has potential adverse effects, such as infection and graft-versus-host disease. Guidelines for RBC transfusion based upon a restrictive policy in the neonate are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H2#H2\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      (EPO) appears to have limited efficacy in decreasing the number of blood donors to which the infant is exposed. It is a costly intervention, and early EPO use may increase the risk and severity of ROP. As a result, we recommend NOT to routinely administer EPO to preterm infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Erythropoietin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A more effective approach to reduce the number of donor exposures for the preterm infant than routine administration of EPO is combination of limiting the amount of blood drawn, a restrictive policy for red cell transfusions, and the use of satellite packs, which allow for repeated transfusions from the same donor to the individual infant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H5#H5\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Target hemoglobin or hematocrit'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H15#H15\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Administration'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Joyce M Koenig, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/1\">",
"      Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000; 27:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/2\">",
"      Stockman JA 3rd, Graeber JE, Clark DA, et al. Anemia of prematurity: determinants of the erythropoietin response. J Pediatr 1984; 105:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/3\">",
"      Brown MS, Phibbs RH, Garcia JF, Dallman PR. Postnatal changes in erythropoietin levels in untransfused premature infants. J Pediatr 1983; 103:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/4\">",
"      Shannon KM, Naylor GS, Torkildson JC, et al. Circulating erythroid progenitors in the anemia of prematurity. N Engl J Med 1987; 317:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/5\">",
"      Rhondeau SM, Christensen RD, Ross MP, et al. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the \"anemia of prematurity\". J Pediatr 1988; 112:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/6\">",
"      Ohls RK, Liechty KW, Turner MC, et al. Erythroid \"burst promoting\" activity in serum of patients with the anemia of prematurity. J Pediatr 1990; 116:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/7\">",
"      Malek A, Sager R, Eckardt KU, et al. Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system. Pflugers Arch 1994; 427:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/8\">",
"      Schneider H, Malek A. Lack of permeability of the human placenta for erythropoietin. J Perinat Med 1995; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/9\">",
"      Widness JA, Schmidt RL, Sawyer ST. Erythropoietin transplacental passage--review of animal studies. J Perinat Med 1995; 23:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/10\">",
"      Palis J, Segel GB. Developmental biology of erythropoiesis. Blood Rev 1998; 12:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/11\">",
"      Brown MS, Garcia JF, Phibbs RH, Dallman PR. Decreased response of plasma immunoreactive erythropoietin to \"available oxygen\" in anemia of prematurity. J Pediatr 1984; 105:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/12\">",
"      Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997; 273:R1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/13\">",
"      Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 1998; 92:3218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/14\">",
"      Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992; 263:F474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/15\">",
"      Flake AW, Harrison MR, Adzick NS, Zanjani ED. Erythropoietin production by the fetal liver in an adult environment. Blood 1987; 70:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/16\">",
"      Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/17\">",
"      Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/18\">",
"      Rajakumar A, Conrad KP. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod 2000; 63:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/19\">",
"      Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics 2000; 106:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/20\">",
"      Ringer SA, Richardson DK, Sacher RA, et al. Variations in transfusion practice in neonatal intensive care. Pediatrics 1998; 101:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/21\">",
"      KAPLAN E, HSU KS. Determination of erythrocyte survival in newborn infants by means of Cr51-labelled erythrocytes. Pediatrics 1961; 27:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/22\">",
"      Shahal Y, Bauminger ER, Zmora E, et al. Oxidative stress in newborn erythrocytes. Pediatr Res 1991; 29:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/23\">",
"      Robles R, Palomino N, Robles A. Oxidative stress in the neonate. Early Hum Dev 2001; 65 Suppl:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/24\">",
"      Haiden N, Schwindt J, Cardona F, et al. Effects of a combined therapy of erythropoietin, iron, folate, and vitamin B12 on the transfusion requirements of extremely low birth weight infants. Pediatrics 2006; 118:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/25\">",
"      Bard H, Fouron JC, Chessex P, Widness JA. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity in infants with bronchopulmonary dysplasia. J Pediatr 1998; 132:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/26\">",
"      Bard H. The postnatal decline of hemoglobin F synthesis in normal full-term infants. J Clin Invest 1975; 55:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/27\">",
"      Bard H, Prosmanne J. Postnatal fetal and adult hemoglobin synthesis is preterm infants whose birth weight was less than 1,000 grams. J Clin Invest 1982; 70:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/28\">",
"      Beuzard Y, Vainchenker W, Testa U, et al. Fetal to adult hemoglobin switch in cultures of early erythroid precursors from human fetuses and neonates. Am J Hematol 1979; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/29\">",
"      Stockman JA 3rd. Anemia of prematurity. Clin Perinatol 1977; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/30\">",
"      Stockman JA 3rd, Garcia JF, Oski FA. The anemia of prematurity. Factors governing the erythropoietin response. N Engl J Med 1977; 296:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/31\">",
"      Stockman JA 3rd, Oski FA. RBC values in low-birth-weight infants during the first seven weeks of life. Am J Dis Child 1980; 134:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/32\">",
"      Lachance C, Chessex P, Fouron JC, et al. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity. J Pediatr 1994; 125:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/33\">",
"      B&ouml;hler T, Janecke A, Linderkamp O. Blood transfusion in late anemia of prematurity: effect on oxygen consumption, heart rate, and weight gain in otherwise healthy infants. Infusionsther Transfusionsmed 1994; 21:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/34\">",
"      Zagol K, Lake DE, Vergales B, et al. Anemia, apnea of prematurity, and blood transfusions. J Pediatr 2012; 161:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/35\">",
"      Madsen LP, Rasmussen MK, Bjerregaard LL, et al. Impact of blood sampling in very preterm infants. Scand J Clin Lab Invest 2000; 60:125.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of Pediatrics. Nutritional needs of the preterm infant. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village 2009. p.79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/37\">",
"      Berseth CL, Van Aerde JE, Gross S, et al. Growth, efficacy, and safety of feeding an iron-fortified human milk fortifier. Pediatrics 2004; 114:e699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/38\">",
"      Birenbaum HJ, Pane MA, Helou SM, Starr KP. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants. South Med J 2006; 99:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/39\">",
"      Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; :CD004863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/40\">",
"      Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004; 114:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/41\">",
"      Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; :CD004868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/42\">",
"      Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012; 10:CD004865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/43\">",
"      Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; :CD004865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/44\">",
"      Ohls RK, Christensen RD. Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurity. J Pediatr 1991; 119:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/45\">",
"      Halp&eacute;rin DS. Use of recombinant erythropoietin in treatment of the anemia of prematurity. Am J Pediatr Hematol Oncol 1991; 13:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/46\">",
"      Carnielli VP, Da Riol R, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 79:F44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/47\">",
"      Bechensteen AG, H&aring;g&aring; P, Halvorsen S, et al. Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake. Eur J Pediatr 1997; 156:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/48\">",
"      Calhoun DA, Christensen RD, Edstrom CS, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000; 27:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/49\">",
"      Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 1996; 128:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20792/abstract/50\">",
"      Ohls RK, Roohi M, Peceny HM, et al. A randomized, masked study of weekly erythropoietin dosing in preterm infants. J Pediatr 2012; 160:790.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4962 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20792=[""].join("\n");
var outline_f20_19_20792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impaired erythropoietin production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Blood loss from phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Reduced red blood cell life span",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Iron depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OXYGEN DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL AND LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Iron supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Early EPO use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Late EPO use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H197405534\">",
"      - Comparison early versus late use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4962|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20793="Treatment of oropharyngeal and esophageal candidiasis";
var content_f20_19_20793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of oropharyngeal and esophageal candidiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20793/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/19/20793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species can be associated with infections involving mucosal membranes, including the oropharynx and esophagus. The majority of these infections are related to Candida albicans. Oropharyngeal infection is often asymptomatic unless it is associated with lower tract disease, which is usually characterized by dysphagia or odynophagia.",
"   </p>",
"   <p>",
"    The treatment of oropharyngeal candidiasis or esophageal candidiasis will be discussed below. The clinical manifestations of oropharyngeal and esophageal candidiasis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OROPHARYNGEAL CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred therapy for the treatment of oropharyngeal candidiasis differs by patient population. The general duration of treatment is 7 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ]. For any given drug, not all individuals with a clinical response will achieve a mycological response; however rates of relapse within one month tend to be lower when a mycological cure is obtained.",
"   </p>",
"   <p>",
"    Considerations for treatment choice include drug effectiveness, severity of infection, ease of administration, anticipated adherence, gastric acidity (which may affect absorption), drug-drug interactions, and cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     HIV-seronegative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of oropharyngeal candidiasis in patients without AIDS is usually accomplished with local antifungal lozenges or solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     Nystatin",
"    </a>",
"    swish and swallow (400,000 to 600,000 units four times daily) has been used for many years, but is not always palatable to patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/4\">",
"     4",
"    </a>",
"    ]. It also contains sucrose, which can cause dental caries when used over prolonged time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/5\">",
"     5",
"    </a>",
"    ]. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troches (one 10-mg troche dissolved slowly five times daily) is effective, but is difficult to adhere to due to frequent dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/4\">",
"     4",
"    </a>",
"    ]. For topical agents, successful therapy depends on adequate contact time between the agent and the oral mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient does not respond to these local measures, the preferred therapy is oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 mg loading dose, then 100 to 200 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,2,6,7\">",
"     1,2,6,7",
"    </a>",
"    ]. Clinical symptoms and signs resolve in more than 90 percent of patients taking fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 279 cancer patients who were receiving cytotoxic drugs, patients were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical cure rate was significantly higher for fluconazole (74 versus 62 percent). The mycological cure rate was also significantly better in those patients treated with fluconazole (80 versus 68 percent). Studies of other alternative therapies have been mainly conducted in HIV-infected patients (see",
"    <a class=\"local\" href=\"#H4\">",
"     'HIV-seropositive patients'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Therapy for denture stomatitis requires treatment of the device as well as the oral cavity to avoid relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/8\">",
"     8",
"    </a>",
"    ]. The dentures must be removed before going to bed, brushed vigorously, and then soaked in a solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    or a product such as Polident or Efferdent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,3,10\">",
"     1,3,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence is common if the underlying risk factors are still present, (eg, ongoing steroid use or chemotherapy). In these patients, oral troches are a reasonable first approach; for more persistent infections, prophylactic therapy with 100 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    daily is a good option. Some patients with radiation-induced xerostomia have recurrent episodes of candidiasis after the radiation therapy is finished. It is probably better to treat when symptoms appear than to give continuous fluconazole suppression, which increases the risk of developing azole resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. Drug-resistant Candida glabrata infection in patients with head and neck cancer has been described in two case series, and in both, higher dosages of fluconazole were required for eradication of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H25\">",
"     'Drug resistance'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HIV-seropositive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis is the most common opportunistic infection in persons infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The development of oropharyngeal candidiasis in an HIV-infected patient is usually associated with significant immunosuppression (CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/13\">",
"     13",
"    </a>",
"    ]. Prior colonization and a history of oral candidiasis are other significant risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of oropharyngeal candidiasis can include topical agents or azole therapy, as discussed below. We recommend use of topical agents for a patient with their first presentation of mild thrush. For patients with moderate to severe oropharyngeal candidiasis or for those with recurrent disease, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    due to its effectiveness, palatability, ease of administration, and cost, as suggested by major guideline committees [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. We also recommend fluconazole rather than topical therapy in patients who are at risk of developing esophageal candidiasis (CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    therapy, with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troches (10 mg troche five times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    suspension (400,000 to 600,000 units four times daily), can be administered during the patient's initial episode of mild oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In studies that have compared clotrimazole troches or nystatin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , clotrimazole had comparable effectiveness to fluconazole, whereas nystatin was clearly inferior.",
"   </p>",
"   <p>",
"    Topical therapies, such as antifungal creams, are also suitable for the treatment of angular cheilitis, which can be seen as a manifestation of candida infection in immunosuppressed hosts. Angular cheilitis manifests as bilateral, bright red erythematous fissures at the angles of the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Azole therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Azole therapies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    has been shown to be effective for oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/20\">",
"     20",
"    </a>",
"    ]. There are few data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , although its efficacy for esophageal candidiasis suggests it would be efficacious for oropharyngeal candidiasis (",
"    <a class=\"graphic graphic_table graphicRef86676 \" href=\"UTD.htm?39/4/40012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized, controlled trials, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    was demonstrated to be as effective and convenient, and better tolerated than topical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. In addition, it is associated with less risk of relapse and a longer disease-free interval [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/18,21,22\">",
"     18,21,22",
"    </a>",
"    ]. The dose recommended is 200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 167 HIV-infected patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      was demonstrated to be more efficacious than topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"       nystatin",
"      </a>",
"      with clinical cure rates of 87 and 52 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/18\">",
"       18",
"      </a>",
"      ]. Mycological cure rates were also superior with fluconazole.",
"     </li>",
"     <li>",
"      In a large study of 334 HIV-infected patients with oral candidiasis, patients were randomly assigned to either 14 days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"       clotrimazole",
"      </a>",
"      troches (10 mg five times daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (100 mg daily). Both therapies were found to be clinically effective (94 percent compared to 98 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, mycological cure during primary therapy is higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    than with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/17\">",
"     17",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/18\">",
"     18",
"    </a>",
"    ] and clinical relapse is more common with nystatin than with azole therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    solution, but not capsules, is as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for the treatment of oropharyngeal candidiasis and more effective than topical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    in mycological cure rates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind trial of 244 HIV-infected patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      oral solution was as clinically effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (90 percent in both groups) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/23\">",
"       23",
"      </a>",
"      ]. The incidence of early relapse (within 30 days) occurred in approximately one-third of both treatment groups; drug tolerability was comparable.",
"     </li>",
"     <li>",
"      In another randomized, controlled trial of 147 patients with mycologically proven oropharyngeal candidiasis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      oral solution (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      200 mg daily for 7 to 14 days) was demonstrated to be as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    solution appears to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    at 200 mg daily, this formulation of itraconazole has been associated with nausea in more than 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ]. Itraconazole capsules, which are more palatable, are less effective due to their variable absorption and should not be used. Itraconazole is also a more potent inhibitor of cytochrome p450 enzymes than fluconazole, which increases the risk of drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    is an extended-spectrum triazole with potent in vitro activity against Candida species, including C. albicans, C. glabrata, and C. krusei (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant strains). In a multicenter, randomized, evaluator-blinded study of 350 HIV-infected patients with oropharyngeal candidiasis, posaconazole (400 mg bid for three days followed by 400 mg once daily), was compared with fluconazole in terms of efficacy, safety and tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/20\">",
"     20",
"    </a>",
"    ]. Both drugs were highly effective in producing favorable outcomes (97 percent in both groups).",
"   </p>",
"   <p>",
"    In an open-label trial in 149 HIV-infected patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    for oropharyngeal candidiasis refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , clinical cure or improvement occurred in 74 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    is unclear at present, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is very effective and much less expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. Posaconazole may be an effective alternative in patients with refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of esophageal candidiasis are secondary to C. albicans. The risk of disease is increased in HIV-infected patients with advanced immunosuppression (CD4 count &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    and in those with oropharyngeal thrush [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, the absence of oropharyngeal thrush does not rule out the possibility of Candida esophagitis. The introduction of potent antiretroviral therapy has been associated with a marked diminution in esophageal candidiasis and in treatment-refractory cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal candidiasis also occurs in HIV-seronegative patients who are taking inhaled corticosteroids and in cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida esophagitis requires systemic antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/16\">",
"     16",
"    </a>",
"    ]; it should never be managed with local agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/2\">",
"     2",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef86676 \" href=\"UTD.htm?39/4/40012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An empiric course of antifungal therapy is appropriate in the immunosuppressed patient with symptoms of odynophagia or dysphagia; endoscopy can be performed if symptoms do not improve after approximately 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/21\">",
"     21",
"    </a>",
"    ]. The threshold for doing endoscopy is lower in patients without evidence of oral thrush, since other etiologies may be causing the patient's symptoms. The general duration of treatment is 14 to 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ]. Intravenous therapy may be required initially in patients with severe disease who cannot take oral therapy.",
"   </p>",
"   <p>",
"    The treatment of esophageal candidiasis can include azoles, echinocandins, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , as discussed below. We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for the treatment of esophageal candidiasis due to its excellent efficacy, ease of administration, and low cost. For patients with documented esophageal candidiasis that is refractory to fluconazole after one week of treatment, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    in outpatients who can still maintain hydration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    oral suspension is also effective, but causes more nausea. In patients in whom intravenous therapy is necessary, we suggest use of an echinocandin, rather than amphotericin B, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Azole therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential agents in the azole class include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    solution,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three randomized trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    was superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for the treatment of esophageal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In a number of trials and smaller studies, the effectiveness of fluconazole therapy has ranged from 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/2,35-40\">",
"     2,35-40",
"    </a>",
"    ]. Its ease of administration, lack of toxicity, and cost also favor its use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. The dose is 400 mg as a loading dose and then 100 to 400 mg daily for 14 to 21 days given orally or intravenously, as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,42\">",
"     1,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized, controlled trials demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    oral solution (200 mg daily) was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/34-36,43\">",
"     34-36,43",
"    </a>",
"    ]. However, itraconazole solution can cause nausea and has the potential for drug interactions due to its effects on cytochrome p450 enzymes. Itraconazole capsules should not be used due to variability of absorption, resulting in compromised efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    also appears to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for the treatment of esophageal candidiasis, and has been used to treat patients who were unresponsive to fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/37,44\">",
"     37,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A double-blind, multicenter trial was performed to evaluate the comparative efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (loading dose of 400 mg followed by 200 mg once daily) or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (200 mg twice daily) for the treatment of proven esophageal candidiasis in 391 immunocompromised patients, most of whom had underlying AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/37\">",
"     37",
"    </a>",
"    ]. Voriconazole and fluconazole resulted in similar rates of microbiologic cure, as assessed by repeat esophagoscopy (98 versus 95 percent, respectively). The most common side effect associated with voriconazole was mild, transient visual disturbances (23 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    oral solution, 400 mg twice daily, led to a clinical response in 32 of 43 patients (74 percent) with endoscopically-documented esophageal candidiasis, which had been refractory to primary therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    ) are also effective for the treatment of Candida esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/38-40,45-48\">",
"     38-40,45-48",
"    </a>",
"    ]. All of the echinocandins must be given intravenously, and therefore, are used mostly in the treatment of hospitalized patients and those patients who have esophageal candidiasis refractory to azole therapy; they are also much more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/4\">",
"     4",
"    </a>",
"    ]. Most studies have shown higher relapse rates with echinocandins than with azoles except at higher dosages of the echinocandins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/38,39,48\">",
"     38,39,48",
"    </a>",
"    ]. For this reason, the recommended doses of some echinocandins for the treatment of esophageal candidiasis are higher than those used for candidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Caspofungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind, randomized trial, 177 patients with esophageal candidiasis were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    (50 mg intravenously) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 mg intravenously) once daily for 7 to 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/38\">",
"     38",
"    </a>",
"    ]. The primary endpoint was the combined response of symptom resolution and significant endoscopic improvement five to seven days after discontinuation of therapy. Favorable responses were seen in 81 percent of patients in the caspofungin arm and 85 percent of patients on the fluconazole arm. Symptoms recurred in 18 (28 percent) of 64 patients given caspofungin and in 12 (17 percent) of 72 patients given fluconazole.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"     Caspofungin",
"    </a>",
"    also appears to be effective in the treatment of esophageal candidiasis resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and is a less toxic alternative to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/49\">",
"     49",
"    </a>",
"    ]. A retrospective analysis of its efficacy was performed in patients with esophagitis who had resistant isolates or a refractory clinical infection (no improvement after one week of fluconazole therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/49\">",
"     49",
"    </a>",
"    ]. Caspofungin led to a favorable clinical response in the majority of patients with in vitro resistant isolates (11 of 14) and in those with clinically refractory disease (7 of 11).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Micafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"     Micafungin",
"    </a>",
"    has been evaluated in the treatment of esophageal candidiasis in HIV-infected patients with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A dose-ranging study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      (12.5, 50, 75, and 100 mg daily) in 120 HIV-infected patients with esophageal candidiasis demonstrated that those who received 75 or 100 mg per day had more favorable clinical and endoscopic outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another dose-ranging study of 245 adults with AIDS and culture proven esophageal candidiasis, the endoscopic cure rate was dose dependent at 69 percent, 77 percent and 90 percent with 50, 100, and 150 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      , respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/39\">",
"       39",
"      </a>",
"      ]. Cure rates at the two higher doses of micafungin were comparable to its comparator,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , at 200 mg daily.",
"     </li>",
"     <li>",
"      In a large, controlled non-inferiority trial of 523 predominantly HIV-infected patients with esophageal candidiasis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       micafungin",
"      </a>",
"      (150 mg) was compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 mg daily) for efficacy and safety [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/48\">",
"       48",
"      </a>",
"      ]. Therapy was given for a mean of 14 days. Endoscopic cure was documented in 88 percent of patients in both arms; relapse rates were 15 percent for micafungin and 11 percent for fluconazole. Based on this study, 150 mg of micafungin is recommended the dose for the treatment of esophageal candidiasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anidulafungin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, double-blind trial in 601 patients with esophageal candidiasis compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , 50 mg daily after a loading dosage of 100 mg, to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. Initial clinical and endoscopic improvement on therapy was similar in both arms (97 percent with anidulafungin versus 99 percent with fluconazole). However, endoscopic relapse was more common in the anidulafungin arm than in subjects treated with fluconazole (53 versus 19 percent). The recommended dosage of anidulafungin for the treatment of esophageal candidiasis is 200 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    (0.3 to 0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) is also an effective agent for Candida esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/51\">",
"     51",
"    </a>",
"    ]. However, its use is limited because it is given intravenously and is associated with more toxicity than other antifungal drugs (eg, the echinocandins).",
"   </p>",
"   <p>",
"    The clinical indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    therapy include, drug resistant candidal infections and esophageal candidiasis during pregnancy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Drug resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Treatment during pregnancy'",
"    </a>",
"    below.) Isolates of C. glabrata and C. krusei may require higher doses of amphotericin B (0.7",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Azoles are teratogenic and should not be used during the first trimester for the treatment of mucosal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/52\">",
"     52",
"    </a>",
"    ]. There are no data regarding the use of echinocandins in pregnancy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short courses of topical therapy rarely result in adverse effects.",
"   </p>",
"   <p>",
"    Azole therapy can be associated with gastrointestinal upset; prolonged administration can cause hepatotoxicity; periodic monitoring of aminotransferases is prudent with chronic administration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is the only azole associated with visual disturbances and has a higher risk of rash, including photosensitivity, than other azoles.",
"   </p>",
"   <p>",
"    Echinocandins are very well tolerated, but require intravenous administration. Drug interactions are uncommon because, unlike the azoles, these drugs are not metabolized via the cytochrome p450 pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergence of drug resistance has been mostly reported for azoles, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/7,54-56\">",
"     7,54-56",
"    </a>",
"    ]. Risk factors in HIV-infected patients include advanced immunosuppression and chronic exposure to azoles [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/56\">",
"     56",
"    </a>",
"    ]. A large, randomized trial performed during the HAART era found that the rate of development of clinical fluconazole resistance was the same for individuals receiving long-term suppressive therapy as for those receiving episodic therapy; however, the Candida isolates recovered from the patients receiving continuous therapy showed reduced susceptibility to fluconazole in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Refractory mucosal candidiasis is sometimes due to non-albicans species, such as C. glabrata or C. krusei [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    resistant candidiasis can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , an echinocandin, or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1,16,21\">",
"     1,16,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-HAART era, the risk of developing resistant candidiasis was related to a CD4 count less than 50 cells and to prolonged azole therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/59\">",
"     59",
"    </a>",
"    ]. Use of HAART has been associated with both declining rates of persistent carriage of C. albicans and reduced frequency of symptomatic episodes of oropharyngeal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In patients with AIDS, HAART plays an important role in preventing recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is effective in the prevention of oropharyngeal candidiasis in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/57\">",
"     57",
"    </a>",
"    ]. However, most HIV specialists do not recommend primary or secondary prophylaxis due to the effectiveness of therapy for acute disease, the low mortality associated with mucosal candidiasis, the potential for resistance and drug interactions, and the associated cost [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/16,21,62\">",
"     16,21,62",
"    </a>",
"    ]. This topic is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some have suggested that prophylaxis can be considered in the individual with frequent or severe mucosal infections or in non-Western settings where the rates of invasive fungal disease, such as cryptococcosis, are much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Patients with a history of one or more episodes of esophageal candidiasis, who have not attained immune reconstitution on antiretroviral therapy, are good candidates for secondary prophylaxis;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    at 100 to 200 mg three times weekly is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/21,57,64\">",
"     21,57,64",
"    </a>",
"    ]. However, prolonged use of systemically absorbed azoles in patients with CD4 counts less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    increases the risk for developing resistance; these implications should be considered in any long-term treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20793/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/54/27489?source=see_link\">",
"       \"Patient information: Thrush (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Oropharyngeal candidiasis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal candidiasis is a local infection of older adults who wear dentures, patients treated with antibiotics, steroids, chemotherapy, or radiation therapy to the head and neck, and those with cellular immune deficiency states, such as AIDS. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend topical therapy for the treatment of oropharyngeal candidiasis in patients without AIDS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oropharyngeal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend topical therapy for the initial episode of oropharyngeal candidiasis in HIV-infected patients with mild disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with recurrent infection, moderate to severe disease, or in those with advanced immunosuppression (CD4 &lt;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days after clinical improvement) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oropharyngeal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Esophageal candidiasis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esophageal candidiasis is most commonly seen in HIV-infected patients with advanced immunosuppression (CD4 &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL).",
"      </span>",
"      The presence of oropharyngeal candidiasis increases the risk of this disease; however, its absence does not eliminate the diagnosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antifungal therapy can be initiated with careful follow-up. Endoscopy should be undertaken if the patient has no improvement of symptoms in 72 hours. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend systemic agents for the treatment of documented or suspected esophageal candidiasis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg loading dose followed by 200 to 400 mg daily for 14 to 21 days) for the treatment of esophageal candidiasis due to its ease of administration, lack of toxicity, and cost (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with documented esophageal candidiasis that is refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      after one week of treatment, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      in outpatients who can still maintain hydration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In patients in whom intravenous therapy is necessary, we suggest use of an echinocandin, rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/1\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/2\">",
"      Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/3\">",
"      Shay K, Truhlar MR, Renner RP. Oropharyngeal candidosis in the older patient. J Am Geriatr Soc 1997; 45:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/4\">",
"      Klotz SA. Oropharyngeal candidiasis: a new treatment option. Clin Infect Dis 2006; 42:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/5\">",
"      Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/6\">",
"      Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990; 34:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/7\">",
"      Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/8\">",
"      Finlay PM, Richardson MD, Robertson AG. A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours. Br J Oral Maxillofac Surg 1996; 34:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/9\">",
"      Oude Lashof AM, De Bock R, Herbrecht R, et al. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer 2004; 40:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/10\">",
"      Iacopino AM, Wathen WF. Oral candidal infection and denture stomatitis: a comprehensive review. J Am Dent Assoc 1992; 123:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/11\">",
"      Redding SW, Dahiya MC, Kirkpatrick WR, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/12\">",
"      Redding SW, Kirkpatrick WR, Coco BJ, et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002; 40:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/13\">",
"      Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/14\">",
"      Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/15\">",
"      MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/16\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/17\">",
"      Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/18\">",
"      Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/19\">",
"      Sharon V, Fazel N. Oral candidiasis and angular cheilitis. Dermatol Ther 2010; 23:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/20\">",
"      Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/21\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/22\">",
"      Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/23\">",
"      Phillips P, De Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/24\">",
"      Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/25\">",
"      Murray PA, Koletar SL, Mallegol I, et al. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997; 19:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/26\">",
"      Posaconazole (Noxafil) for invasive fungal infections. Med Lett Drugs Ther 2006; 48:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/27\">",
"      Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/28\">",
"      Wilcox CM, Straub RF, Clark WS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/29\">",
"      Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/30\">",
"      Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol 2003; 98:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/31\">",
"      Samonis G, Skordilis P, Maraki S, et al. Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer. Clin Infect Dis 1998; 27:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/32\">",
"      Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/33\">",
"      Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Endoscopy 1995; 27:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/34\">",
"      Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis. Gastroenterology 1996; 111:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/35\">",
"      Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/36\">",
"      Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/37\">",
"      Ally R, Sch&uuml;rmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/38\">",
"      Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/39\">",
"      de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/40\">",
"      Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/41\">",
"      Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/43\">",
"      Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 2000; 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/44\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/45\">",
"      Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/46\">",
"      Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/47\">",
"      Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/48\">",
"      de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/49\">",
"      Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr 2002; 31:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/50\">",
"      Anidulafungin (Eraxis) for Candida infections. Med Lett Drugs Ther 2006; 48:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/51\">",
"      Lake DE, Kunzweiler J, Beer M, et al. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996; 42:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/52\">",
"      Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/53\">",
"      Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/54\">",
"      Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000; 30:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/55\">",
"      Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/56\">",
"      Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/57\">",
"      Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005; 41:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/58\">",
"      Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997; 25:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/59\">",
"      Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/60\">",
"      Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/61\">",
"      Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999; 21:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Rapid assessment of injuries among survivors of the terrorist attack on the World Trade Center--New York City, September 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/63\">",
"      Bozzette SA. Fluconazole prophylaxis in HIV disease, revisited. Clin Infect Dis 2005; 41:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20793/abstract/64\">",
"      Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:700.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2432 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20793=[""].join("\n");
var outline_f20_19_20793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OROPHARYNGEAL CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HIV-seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HIV-seropositive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Azole therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ESOPHAGEAL CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Azole therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Caspofungin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Micafungin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anidulafungin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ADVERSE EFFECTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Oropharyngeal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/4/40012\" title=\"table 1\">",
"      Treatment of nongenital mucocutaneous candidiasis for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/54/27489?source=related_link\">",
"      Patient information: Thrush (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20794="Medical management of type 1 and type 2 diabetes mellitus in pregnant women";
var content_f20_19_20794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Rhonda Bentley-Lewis, MD, MBA, MMSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/19/20794/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/19/20794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregestational diabetes (ie, diabetes diagnosed before pregnancy, type 1 or type 2 diabetes mellitus) comprises approximately 13 percent of all diabetes in pregnancy, while gestational diabetes (ie, GDM, diabetes with onset or first recognition in pregnancy) comprises the remaining 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of pregestational diabetes has been increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/1\">",
"     1",
"    </a>",
"    ] due to the increasing prevalence of type 2 diabetes in women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of GDM is also increasing, paralleling the increasing prevalence of obesity and undiagnosed type 2 diabetes in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mainstay of the medical management of pregestational diabetes involves frequent monitoring of blood glucose levels with adjustment of diet and insulin therapy to achieve normoglycemia. Normoglycemia is important because maintenance of maternal blood glucose concentration at or near normoglycemic levels decreases the likelihood of adverse pregnancy outcomes, such as miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/4\">",
"     4",
"    </a>",
"    ], congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/5\">",
"     5",
"    </a>",
"    ], macrosomia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/6\">",
"     6",
"    </a>",
"    ], and fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/7\">",
"     7",
"    </a>",
"    ]. Ideally, normoglycemia is achieved before conception and maintained through the postpartum period. Since the American Diabetes Association (ADA) suggests that a reasonable goal hemoglobin A1c (A1C) target for non-pregnant adults is &lt;7.0 percent, pregnant women, ideally, will not have to make substantial therapeutic modifications in order to achieve the more intensive",
"    <span class=\"nowrap\">",
"     preconception/pregnancy",
"    </span>",
"    A1C goal of &lt;6.0 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The medical management of pregestational diabetes mellitus during pregnancy will be reviewed here. Multiple additional aspects of pregnancy complicated by diabetes are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"       \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=see_link\">",
"       \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"       \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"       \"Medical management and follow-up of gestational diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSING GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspects of glucose monitoring and glycemic control specific to pregnancy are discussed below. Detailed descriptions of blood glucose monitoring, including self-monitoring of blood glucose, urine ketones, blood glucose meters, glucose strips, and continuous glucose monitoring, are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glycated hemoglobin (A1C)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21818703\">",
"    <span class=\"h3\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cells that have been recently released from the bone marrow into the circulation have a very low concentration of glycated hemoglobin; the concentration increases over time and with increasing exposure to glucose. The total glycated hemoglobin level is reasonably approximated by measurement of hemoglobin A1C since it accounts for approximately 92 percent of all glycated hemoglobin. In nonpregnant individuals, the A1C level in blood reflects the mean age of the red blood cells and the mean glucose concentration to which they have been exposed over the previous 8 to 12 weeks. When used clinically to assess glycemic control over time, it is assumed that the mean age of the red blood cells remains constant and that changes in A1C concentration only reflect changes in glucose concentration.",
"   </p>",
"   <p>",
"    In pregnant women, however, physiologic changes related to pregnancy also contribute to changes in A1C. In pregnant nondiabetic women, A1C falls to a nadir in the midtrimester and rises in the third trimester. These changes in A1C are caused by physiologic changes in mean glucose concentration during pregnancy and from physiologic changes in mean red blood cell age (mean red blood cell age falls in pregnancy as red blood cell mass increases to meet volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/9\">",
"     9",
"    </a>",
"    ]). As a result, pregnant women have lower A1C levels compared with nonpregnant women. For this reason, several investigators have suggested use of a pregnancy specific reference range for A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], some have advised against using the A1C during the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/2\">",
"     2",
"    </a>",
"    ], while others have proposed that the A1C goal in late pregnancy should be lowered by 0.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/13\">",
"     13",
"    </a>",
"    ]. We recommend use of A1C goal &lt;6.0 percent throughout pregnancy, interpreted with an understanding of the physiologic changes in A1C concentration across gestation. Despite the shortcoming of the A1C value in pregnancy, monitoring A1C is still useful as a correlate of mealtime glycemia, as well as neonatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21818696\">",
"    <span class=\"h3\">",
"     Measurement and target A1C level",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the American Diabetes Association (ADA) clinical practice guideline for managing preexisting diabetes in pregnancy that recommends monthly A1C determinations beginning with the initial prenatal visit and an A1C goal &lt;6.0 percent throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ], if safely achievable without inducing hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. The guideline, which is at the level of expert consensus or clinical experience, also specifies that a Diabetes Control and Complications Trial (DCCT)-aligned assay be used for measurement of A1C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for choosing this target A1C is that, in observational studies, metabolic control variably defined as nearly &ldquo;normal&rdquo; as possible is associated with the lowest rates of adverse events. In the first trimester, this means rates of congenital anomalies (2.5 to 4 percent) and miscarriage (15 percent) that are similar to the rates in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/16\">",
"     16",
"    </a>",
"    ]. Higher A1C values (&ge;6.1 percent) during pregnancy, especially in the third trimester, have been associated with a significant increase in risk of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/17\">",
"     17",
"    </a>",
"    ] and delivery of a large for gestational age infant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/18\">",
"     18",
"    </a>",
"    ]. However, hypoglycemia is more common with strict glycemic control and studies have not rigorously evaluated the risk versus benefit of this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with type 1 or type 2 diabetes should measure their blood glucose concentration frequently so that timely adjustments to diet, insulin, or anti-hyperglycemic therapy can be made to prevent or treat hyper- and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. Knowledge of glucose concentration and appropriate intervention to achieve normoglycemia is also central to efforts at reducing maternal, obstetrical, and neonatal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/19\">",
"     19",
"    </a>",
"    ]. Elevated blood glucose levels are associated with diabetes complications, such as worsening nephropathy and retinopathy, and pregnancy complications, such as preeclampsia, preterm labor, and delivery of a large for gestational age infant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. Several studies have reported the beneficial effects of improved glycemic control on fetal outcome in pregnant women with pregestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ]. The most consistent effect demonstrated in these studies is a reduction in rate of macrosomia, which is desirable because macrosomia increases the risk of shoulder dystocia and cesarean delivery. A reduction in preeclampsia appears to be another benefit. The incidence of preeclampsia is lowest in women with optimal glycemic control and increases as A1C increases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3995393\">",
"    <span class=\"h3\">",
"     Self-monitoring of blood glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In nonpregnant individuals, the American Diabetes Association (ADA) generally recommends self-monitoring of blood glucose (SMBG) three or more times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]; however, for pregnant women with preexisting diabetes, they suggest SMBG before and one hour after the first bite of each meal, at bedtime, and occasionally between 2 AM and 4 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. We agree with this approach rather than the alternative two-hour postprandial assessment as postprandial glucose concentrations peak 60 to 90 minutes after eating [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In addition, assessment at 2 AM to 4 AM is critical if nocturnal hypoglycemia is suspected in order to identify, treat, and prevent subsequent hypoglycemic events.",
"   </p>",
"   <p>",
"    There are several causes of early morning hyperglycemia. The dawn phenomenon refers to the increase in blood glucose that usually occurs between 3 AM and 5 AM and not preceded by hypoglycemia; it is related to the normal overnight release of hormones associated with insulin resistance. In contrast, the Somogyi effect refers to rebound hyperglycemia that occurs 6 to 12 hours after hypoglycemia and thought to be related to release of counter-regulatory hormones in response to low blood glucose levels. High morning blood glucose levels may also result from inadequate insulin management or carbohydrate snack consumption at bedtime. In order to distinguish among these possibilities, early morning blood sugar assessment (between 3 AM and 5 AM) and review of insulin administration and dietary habits are necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Target blood glucose values",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) have both published recommendations for target blood glucose values based upon consensus expert opinions. Both sets of recommendations broadly overlap one another and, if met, would result in &ldquo;excellent&rdquo; control by any definition. There is no compelling evidence to choose one set over the other. The capillary glucose targets are:",
"   </p>",
"   <p>",
"    &nbsp;ACOG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting glucose concentrations &le;95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Preprandial glucose concentrations no higher than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      One-hour postprandial glucose concentrations no higher than 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Two-hour postprandial glucose concentrations no higher than 120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Mean capillary glucose 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and glycated A1C &le;6 percent",
"     </li>",
"     <li>",
"      During the night, glucose levels should not decrease to less than 60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;ADA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preprandial, bedtime, and overnight glucose concentrations 60 to 99",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3 to 5.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Peak postprandial glucose concentrations 100 to 129",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      one to two hours after the beginning of the meal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Deleterious effects of strict glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence of benefit from very strict (61",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.33",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    to 91",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    versus moderate to strict fasting glucose targets (81",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.45",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    to 116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [6.38",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    although data are sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/26\">",
"     26",
"    </a>",
"    ]. The two potential hazards of intensified glycemic control are hypoglycemia and transient exacerbation of diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/27\">",
"     27",
"    </a>",
"    ]. Frequent glucose monitoring and patient education may help to reduce these risks.",
"   </p>",
"   <p>",
"    The threshold for hypoglycemia in the nonpregnant population is controversial, with some favoring a value of &lt;63",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to avoid over-classification of hypoglycemia in asymptomatic patients. It should be noted that fasting blood glucose values are lower in pregnant women than in nonpregnant women. Whether the increased risk for potentially severe hypoglycemia that will likely occur with strict glucose targets will be balanced by improved fetal outcomes has not been established and caution is required.",
"   </p>",
"   <p>",
"    Although maintenance of near-normoglycemia ultimately slows the development and progression of diabetic retinopathy, it may transiently worsen after intensification of glycemic therapy in both nonpregnant and pregnant hyperglycemic women, with a particular increase in the formation of soft exudates (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"UTD.htm?28/32/29197\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The degree to which this occurs during pregnancy is related to the baseline level of retinal disease and to the magnitude of the reduction of chronic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/30\">",
"     30",
"    </a>",
"    ]. The Diabetes in Early Pregnancy study found that, among 140 women who did not have proliferative retinopathy at the time of conception, progression of retinopathy occurred in 10 percent of those who had no retinopathy, 21 percent of those with mild background retinopathy, and 55 percent of those with severe nonproliferative retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/28\">",
"     28",
"    </a>",
"    ]. This worsening is thought to be mediated by closure of small retinal blood vessels that were narrowed but patent.",
"   </p>",
"   <p>",
"    We recommend a baseline comprehensive eye examination for all women with pregestational diabetes, ideally prior to conception [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. The American Diabetes Association (ADA) recommends an examination during the first trimester and &ldquo;close follow-up throughout pregnancy&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. For women without retinopathy at baseline, we repeat ophthalmologic examinations at least once each trimester and more frequently at the discretion of the ophthalmologist. Close follow-up should continue during the first year postpartum, with the frequency based on disease severity and at the discretion of the ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. Recommendations for women with retinopathy are detailed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link&amp;anchor=H12#H12\">",
"     \"Classification and clinical features of diabetic retinopathy\", section on 'Worsening during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Very strict glycemic control may impair fetal growth and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/31\">",
"     31",
"    </a>",
"    ]. This was illustrated in a study in which the overall incidence of small-for-gestational (SGA) age infants was significantly higher among women with mean blood glucose level throughout pregnancy &le;86",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.8",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    (incidence of SGA: 20 versus 11 percent with less strict glycemic control) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/31\">",
"     31",
"    </a>",
"    ]. However, hypoglycemia does not appear to be teratogenic in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19751990\">",
"    <span class=\"h2\">",
"     Monitoring urine ketones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) is both a medical and an obstetrical emergency because it is associated with risks to the mother and the fetus (demise, developmental delay in childhood). The most common precipitating factors are infection and discontinuation or inadequate insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Precipitating factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DKA usually occurs with blood glucose values exceeding 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/7\">",
"     7",
"    </a>",
"    ]. Ten to 30 percent of DKA in pregnancy has been observed with blood glucose levels &lt;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/32\">",
"     32",
"    </a>",
"    ]. In the setting of hyperglycemia, women with moderate to large ketonuria should alert their physician immediately so that additional insulin can be prescribed promptly. Ideally, the woman should know exactly how much additional insulin is needed if the blood glucose elevation is associated with ketonuria in order to minimize the delay in administration of the appropriate insulin dosage.",
"   </p>",
"   <p>",
"    In the absence of hyperglycemia, ketonuria indicates a catabolic state, which can occur in anyone who has a negative caloric balance. Ketonemia does not accompany ketonuria in this setting. Ketonuria can be corrected by an increase in caloric intake, and particularly increased carbohydrate, matched with adjustments in insulin doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEDICAL NUTRITION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus recommendations for management of diabetes in pregnancy advise individualized medical nutrition therapy (MNT) supervised by a registered dietician with expertise in MNT during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19752084\">",
"    <span class=\"h2\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal diet to maintain glycemic control during pregnancy takes into account caloric intake, carbohydrate content, and distribution of meals throughout the day. The goals of MNT are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provide adequate nutrient intake for a healthy pregnancy",
"     </li>",
"     <li>",
"      Achieve normoglycemia",
"     </li>",
"     <li>",
"      Provide adequate weight gain",
"     </li>",
"     <li>",
"      Provide appropriate food, physical activity, and behavior education",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A synopsis of nutritional therapy of the diabetic gravida is provided below. A detailed review of MNT for nonpregnant individuals with diabetes can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Calorie requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caloric recommendations in pregnancy may be based on Total Energy Expenditure (TEE) calculations, using the Harris Benedict formula [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/33\">",
"     33",
"    </a>",
"    ] for healthy body mass index (BMI) or Mifflin St Jeor formula for",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    BMI categories [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/34\">",
"     34",
"    </a>",
"    ]. Caloric requirements for a singleton pregnancy are increased by an average of approximately 300",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    above basal daily needs in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest caloric intake to provide total gestational weight gain in the range recommended by the Institute of Medicine (IOM) (",
"    <a class=\"graphic graphic_table graphicRef75820 \" href=\"UTD.htm?18/50/19244\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/36\">",
"     36",
"    </a>",
"    ]. These recommendations are based on pre-pregnancy BMI; clinical judgment and provider-patient discussions regarding diet and physical activity will influence the weight achieved within these ranges. In addition, women with twin gestations will have higher weight gain targets.",
"   </p>",
"   <p>",
"    Excessive weight gain should be avoided as it, like hyperglycemia, contributes to development of macrosomia and thus can potentially negate some of the benefits of good glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal obesity can cause excessive fetal growth, independent of diabetes, and often worsens impaired glucose tolerance in both type 1 and type 2 diabetes. Despite these concerns, the safety of weight loss during pregnancy has not been proven and is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link&amp;anchor=H21938069#H21938069\">",
"     \"Weight gain and loss in pregnancy\", section on 'Effect of weight loss in obese women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19752207\">",
"    <span class=\"h2\">",
"     Caloric composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional intake is divided among the macronutrient components to promote optimal glycemic control and avoidance of hypoglycemia and ketonemia. We agree with the American College of Obstetricians and Gynecologists (ACOG) suggested guideline [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complex, high-fiber carbohydrates &mdash; 40 to 50 percent of total calories",
"     </li>",
"     <li>",
"      Protein &mdash; 20 percent of total calories",
"     </li>",
"     <li>",
"      Fats &mdash; 30 to 40 percent of total calories, primarily unsaturated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postprandial blood glucose concentrations are directly dependent upon the carbohydrate content of a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/38\">",
"     38",
"    </a>",
"    ]. The postprandial glucose rise, therefore, can be blunted if the diet is carbohydrate restricted. Complex carbohydrates, such as those in vegetables, are more nutrient dense and raise postprandial blood glucose concentrations less than simple sugars. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link&amp;anchor=H20#H20\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\", section on 'Nutritional content'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Calorie distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Diabetes Association (ADA) recommends three meals per day and snacks &ldquo;as needed&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/39\">",
"     39",
"    </a>",
"    ]. Caloric intake may be distributed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breakfast &mdash; 10 to 20 percent of total calories. Because insulin resistance is greatest in the morning, this is the smallest meal and carbohydrate intake is limited to maintain postprandial normoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lunch &mdash; 20 to 30 percent of total calories",
"     </li>",
"     <li>",
"      Dinner &mdash; 30 to 40 percent of total calories",
"     </li>",
"     <li>",
"      Snacks &mdash; Up to 30 percent of total calories. Snacking is based on caloric needs, support for hypoglycemia, as well as consideration of pre-pregnancy BMI, as overweight and obese women may not need to snack. Bedtime snacks are often needed to minimize nocturnal hypoglycemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19752255\">",
"    <span class=\"h2\">",
"     Supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prenatal multivitamin is appropriate given data that nutritional intake in pregnant diabetic women may be insufficient in calcium, vitamins C and E, copper, magnesium, and zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, we suggest intake of at least 400 to 800 mcg daily of folic acid through supplementation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fortified food sources [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=see_link&amp;anchor=H106393937#H106393937\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'Other conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21821269\">",
"    <span class=\"h2\">",
"     Non-caloric sweeteners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-caloric sweeteners, such as aspartame, may be used in moderation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H25#H25\">",
"     \"Nutrition in pregnancy\", section on 'Artificial sweeteners'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19752326\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of glycemic control desirable during pregnancy in women with type 1 and type 2 diabetes can usually be achieved only with intensive insulin therapy. A consensus statement of the American Diabetes Association (ADA) recommends insulin for optimal glycemic control in pregnant women with type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists (ACOG) also recommends insulin therapy and states use of oral agents for control of type 2 diabetes mellitus during pregnancy should be limited and individualized until more data confirming safety and efficacy become available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not start oral agents during pregnancy. However, increasingly, patients with type 2 diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polycystic ovary syndrome and impaired glucose tolerance are conceiving while on oral anti-hyperglycemic agents. We generally continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in patients who are on this drug, but discontinue other oral agents. We then initiate insulin therapy as needed to achieve adequate metabolic control.",
"   </p>",
"   <p>",
"    Ideally, insulin should be started prior to conception to optimize glycemic control during the critical period of organogenesis early in the first trimester. Insulin requirements during the first trimester are similar to those prior to pregnancy in women with type 1 and type 2 diabetes. During the second half of pregnancy, insulin requirements increase disproportionately in women with type 2 compared with type 1 diabetes. In one study, for example, insulin doses in the third trimester were 1.6",
"    <span class=\"nowrap\">",
"     U/kg/day",
"    </span>",
"    in type 2 diabetes compared with 1.2",
"    <span class=\"nowrap\">",
"     U/kg/day",
"    </span>",
"    in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective use of insulin requires an understanding of the major variables that affect the degree of glycemic control: the insulin preparation, the size of the subcutaneous depot, injection technique, the site of injection, and subcutaneous blood flow. Issues with respect to insulin therapy in pregnant women are addressed below. A detailed discussion on use of insulin in management of diabetes in nonpregnant diabetic women can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734996097\">",
"    <span class=\"h3\">",
"     Type of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of insulin preparations of low antigenicity will minimize the transplacental transport of insulin antibodies: human insulin is the least immunogenic of the commercially available preparations. The three rapid acting insulin analogs (lispro, aspart, glulisine) are comparable in immunogenicity to human regular (clear zinc insulin, CZI) insulin, but only lispro and aspart have been investigated in pregnancy and shown to have acceptable safety profiles, minimal transfer across the placenta, and no evidence of teratogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. These two insulin analogs have also been shown to reduce the risk of postprandial glycemic excursion and delayed postprandial hypoglycemia compared with regular human insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/45\">",
"     45",
"    </a>",
"    ]. In an observational study, use of lispro resulted in similar pregnancy outcomes as human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , but with increased patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longer-acting insulin analogs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    ) have not been studied extensively in randomized trials of pregnant women. A meta-analysis of observational data from 331 pregnancies with glargine exposure during the first, second,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    third trimester showed no increase in any maternal or neonatal adverse outcome compared with use of NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the number of women that have been treated with this drug in the first trimester is too small to assure its safety with respect to congenital malformations. The incidence of macrosomia remained high in glargine treated women and was similar to that with routine care, which resulted in macrosomia in about 20 percent of pregnancies. A disadvantage of glargine is that its activity remains constant over 24 hours, and this level of activity may not be optimal for both daytime and nighttime basal needs. The slow kinetics of glargine insulin may also be problematic during the third trimester when frequent, relatively large changes in insulin dose may be required.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     Insulin detemir",
"    </a>",
"    is another long-acting insulin, and thus subject to similar limitations in titration during the course of a 24-hour period. However, in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    , in 2012, insulin detemir received United States Food and Drug Administration (FDA) approval for reclassification to pregnancy category B from pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). This reclassification was based on data assessing maternal efficacy judged by A1C and safety judged by hypoglycemic episodes in a randomized trial that compared insulin detemir with Neutral Protamine Hagedorn (NPH) insulin in 310 pregnant women with type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/48\">",
"     48",
"    </a>",
"    ]. Detemir was non-inferior to NPH with respect to hypoglycemia rates and A1C achieved. The pharmaceutical package insert notes that no differences in pregnancy outcomes or the health of the fetuses and newborns were seen with insulin detemir compared to NPH, but the full study data are not yet available for review.",
"   </p>",
"   <p>",
"    We recommend use of NPH insulin during pregnancy. The safety (pregnancy category B) and effectiveness of NPH in pregnancy are supported by abundant observational data published over decades. Importantly, doses can be adjusted frequently and quickly in response to variable caloric intake and insulin sensitivity in pregnant women. We do not consider the available data on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    sufficiently compelling to recommend routine use of this insulin instead of NPH in pregnancy. However, if a patient has well-controlled glucose levels on insulin detemir prior to pregnancy, the provider may reasonably choose to continue it, with ongoing assessment of glycemic control during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H6#H6\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approximate times of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef83634 \" href=\"UTD.htm?27/23/28027\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734996107\">",
"    <span class=\"h3\">",
"     Insulin requirements across gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total daily insulin requirements vary during gestation. Observational studies have shown that after an early rise in insulin requirements (between gestational weeks 3 and 7 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/49\">",
"     49",
"    </a>",
"    ]), there is often a significant decline in the early second trimester (between weeks 7 and 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/49\">",
"     49",
"    </a>",
"    ]), followed by a rise during the remainder of pregnancy (especially between weeks 28 and 32 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/49\">",
"     49",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. These changes in insulin requirements likely reflect pregnancy-related alterations in glucose homeostasis, as well as efforts to improve glycemic control and decreased caloric intake in women with nausea and vomiting of pregnancy.",
"   </p>",
"   <p>",
"    Insulin requirements sometimes fall after 35 weeks of gestation. This is observed more often in women with type 1 diabetes than in women with gestational diabetes mellitus (GDM), and in women with longer duration of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/50,52-54\">",
"     50,52-54",
"    </a>",
"    ]. A fall in insulin dose greater than 5 to 10 percent should lead to an assessment of fetal well-being and a search for medical conditions that could account for the drop, since decreasing insulin requirements could be due to placental insufficiency or decreased maternal intake or vomiting. If fetal well-being is confirmed, then a fall in insulin requirement is not associated with adverse fetal outcome and is not an indication for delivery. Falls of up to 30 percent with good pregnancy outcome have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/50,55\">",
"     50,55",
"    </a>",
"    ]. The reduced need for insulin may be related to increased fetal demand for maternal glucose, increased maternal sensitivity to insulin in the fasting state,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a decrease in human chorionic somatomammotropin (formerly human placental lactogen); the latter has been observed in women with GDM [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/50,53,56-58\">",
"     50,53,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3995472\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average insulin requirement in pregnant women with type 1 diabetes is 0.7",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    in the first trimester, often increasing to 0.8",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    for weeks 13 to 28, 0.9",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    for weeks 29 to 34, and 1.0",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    for weeks 35 to term; however, the range of change in insulin requirements is broad. In one study of 237 pregnancies in women with type 1 diabetes, the mean daily insulin requirement increased by 52 units [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/50\">",
"     50",
"    </a>",
"    ]. A large maternal weight gain was associated with a greater increase in the insulin requirement. Massively obese women may need initial doses of 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    in order to overcome the insulin resistance that results from the combination of pregnancy and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meal related",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    and aspart doses are calculated as 50 percent of the insulin requirement. For most pregnant women, this dose is approximately 0.15 times their pregnant weight in kilograms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, an 80 kilogram pregnant diabetic woman would take 12 units of lispro or aspart before each meal. The other 50 percent of her insulin dose should cover basal needs. The dose is calculated as 0.45 times the patient's weight in kilograms. For example, our 80 kilogram women would take 18 units of NPH twice daily. The first dose is given before breakfast and the second dose is given either before dinner with a rapid acting insulin or at bedtime, whichever works best for avoiding nocturnal hypoglycemia. Although there are no clinical trials to show the safety or efficacy of the long acting insulin analogues glargine and detemir in pregnancy, some clinicians use these drugs. For our 80 kilogram woman, the dose would be 36 units of glargine once a day or 18 units of detemir twice a day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19752455\">",
"    <span class=\"h3\">",
"     Method of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in the therapy of type 1 diabetes in the non-pregnant state, multiple (&gt;3) daily injections (MDI) are often used in pregnant women with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"     8",
"    </a>",
"    ]. A two-injection regimen rarely achieves glucose and A1C goals, and can cause nocturnal hypoglycemia with intermediate-acting insulin given at dinner time.",
"   </p>",
"   <p>",
"    Some clinicians use a continuous subcutaneous insulin infusion (CSII) in order to achieve optimal glycemic control during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A systematic review including six randomized trials that compared use of MDI to CSII in pregnant women found no significant differences between groups in glycemic control or pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/63\">",
"     63",
"    </a>",
"    ]. Outcomes evaluated included third trimester A1C, frequency of maternal and neonatal hypoglycemia, and the rates of preterm birth, cesarean delivery, stillbirth, and large or small for gestational age infants. The risk of acidosis with CSII after accidental catheter disconnects is potentially hazardous to mother and fetus. Thus, we feel there is inadequate evidence for recommending CSII over MDI.",
"   </p>",
"   <p>",
"    In general, if a woman is using CSII effectively prepregnancy, there is no need to discontinue this approach. However, even women with good glycemic control can expect a three-fold increase in insulin requirements from preconception to 36 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/64\">",
"     64",
"    </a>",
"    ]. We do not usually start women on insulin pumps during pregnancy because of an increased risk of ketosis (OR 3.26, 95% CI 0.47-22.73 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/63\">",
"     63",
"    </a>",
"    ]), difficulty with catheters with the gravid abdomen, and cost. Most pregnant women require at least two to three basal infusion rates in a 24-hour period, in particular an increased rate in the early morning hours (5 to 9 AM) to counteract the increased release of the anti-insulin hormones cortisol and growth hormone. A protocol for calculating infusion rates has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral anti-hyperglycemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-pregnant women with type 2 diabetes, use of oral anti-hyperglycemic agents (OHAs) is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .) However, the American Diabetes Association (ADA) consensus statement advises discontinuation of these agents and initiation of insulin therapy as soon as possible in pregnancy due to concerns regarding their ability to provide adequate glycemic control and the implications of transplacental passage causing potential fetal and neonatal effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. There are no data from randomized trials to help in making this decision.",
"   </p>",
"   <p>",
"    Although it has been suggested that the use of OHAs may lead to improved glycemic control compared with insulin therapy because of better compliance, this hypothesis has not been tested clinically, nor has there been a trial in pregnant women with type 2 diabetes. Available data indicate that OHAs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , may be both safe and effective alternatives to insulin, but only in women with gestational diabetes mellitus who cannot be adequately treated with diet alone or simply refuse to take insulin. Whether or not OHAs should be considered in pregnant women with type 2 diabetes who are not compliant with, or do not want to take, insulin injections remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/66\">",
"     66",
"    </a>",
"    ]. OHAs are not as effective as insulin in all women with gestational diabetes, such as those with more severe degrees of hyperglycemia early in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/67\">",
"     67",
"    </a>",
"    ], and use of these drugs in pregnancy has not been addressed by the FDA.",
"   </p>",
"   <p>",
"    However, several studies have not found harmful effects from use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    in either early or late pregnancy and have reported effective glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/68-77\">",
"     68-77",
"    </a>",
"    ]. In particular, maternal to fetal passage of glyburide through the placenta is very low, probably due to high protein binding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/78\">",
"     78",
"    </a>",
"    ]. Several observational series have also reported generally good outcomes with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    in pregestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/68,69,79\">",
"     68,69,79",
"    </a>",
"    ], and a meta-analysis found no evidence of an increased risk for major malformations when metformin was taken during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/80\">",
"     80",
"    </a>",
"    ]. The British National Institute for Health and Clinical Excellence (NICE) guideline states that metformin may be used for women with pregestational diabetes as an adjunct or alternative to insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on the use of other OHAs in pregnancy. We suggest not prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    (first generation sulfonylureas) in women with type 2 diabetes because these drugs cross the placenta and can cause fetal hyperinsulinemia, which can lead to macrosomia and prolonged neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. The only thiazolidinedione currently generally available in the US is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    and there are no data available regarding its effect on the fetus. There are limited to no data on the safety or efficacy of meglitinides, alpha-glucosidase inhibitors, or dipeptidyl peptidase-4 inhibitors in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The approach to switching patients from oral anti-hyperglycemic agents to insulin is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link&amp;anchor=H17#H17\">",
"     \"Insulin therapy in type 2 diabetes mellitus\", section on 'Switching to insulin monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ROLE OF EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient and provider should discuss the role of exercise during pregnancy and consider potential medical and obstetrical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ]. Exercise may provide several maternal benefits, including minimizing weight gain, improving glycemic control, and preparing for the physical rigor of labor, as well as fetal benefits, such as reducing fetal adiposity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15,85\">",
"     15,85",
"    </a>",
"    ]. However, there are absolute and relative contraindications to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=see_link&amp;anchor=H4#H4\">",
"     \"Recommendations for exercise during pregnancy and the postpartum period\", section on 'Obstetrical screening'",
"    </a>",
"    .) In the absence of these contraindications, 30 or more minutes of moderate intensity, low fall-risk, physical activity can be performed by women on most days of the week [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15,87,88\">",
"     15,87,88",
"    </a>",
"    ]. Hypoglycemia may occur to a greater degree in pregnancy compared with a non-pregnant state, so a carbohydrate-based snack prior to exercise may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTRAPARTUM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=see_link\">",
"     \"Intrapartum and postpartum management of insulin and blood glucose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"       \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin A1C (A1C) should be measured monthly, acknowledging that second and third trimester values are less reflective of true glycemic control. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glycated hemoglobin (A1C)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We agree with the American Diabetes Association (ADA) suggestion to target preprandial, bedtime, and overnight glucose concentrations of 60 to 99",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3 to 5.5",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      peak postprandial glucose concentrations of 100 to 129",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      one to two hours after the beginning of the meal; and A1C less than 6.0 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Target blood glucose values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Self monitoring of blood glucose should be performed as needed to achieve A1C and glycemic targets, generally, pre-meals and one hour after breakfast, lunch, dinner, and at bedtime (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Women should also monitor blood glucose concentration during the night if nocturnal hypoglycemia is suspected. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary ketones should be measured during illness or when any blood glucose value is over 180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in a type 1 diabetic pregnant woman. (See",
"      <a class=\"local\" href=\"#H19751990\">",
"       'Monitoring urine ketones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with type 1 diabetes require insulin therapy. We suggest a combination of lispro or aspart insulin and Neutral Protamine Hagedorn (NPH) insulin for therapy in pregnancy, as opposed to other types of insulin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with type 2 diabetes who are not able to achieve and maintain target glycemic levels with medical nutritional therapy alone should be managed with insulin therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oral anti-hyperglycemic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moderate, low-risk exercise can be performed during pregnancy in women who have no medical or obstetrical contraindications to this level of physical activity (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Role of exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8374866\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to acknowledge Dr. Lois Jovanovic, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wier LM, Witt E, Burgess J, Elixhauser A. A Healthcare Cost and Utilization Project. Statistical Brief 102. Hospitalizations Related to Diabetes in Pregnancy 2008, Agency for Health Care Policy and Research, Rockville, MD. 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/2\">",
"      Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/3\">",
"      Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/4\">",
"      Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/5\">",
"      Schaefer UM, Songster G, Xiang A, et al. Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 1997; 177:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/6\">",
"      Ehrlich SF, Crites YM, Hedderson MM, et al. The risk of large for gestational age across increasing categories of pregnancy glycemia. Am J Obstet Gynecol 2011; 204:240.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/7\">",
"      Beischer NA, Wein P, Sheedy MT, Steffen B. Identification and treatment of women with hyperglycaemia diagnosed during pregnancy can significantly reduce perinatal mortality rates. Aust N Z J Obstet Gynaecol 1996; 36:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/8\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/9\">",
"      Lurie S. Changes in age distribution of erythrocytes during pregnancy: a longitudinal study. Gynecol Obstet Invest 1993; 36:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/10\">",
"      Mosca A, Paleari R, Dalfr&agrave; MG, et al. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem 2006; 52:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/11\">",
"      Radder JK, van Roosmalen J. HbA1c in healthy, pregnant women. Neth J Med 2005; 63:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/12\">",
"      Nielsen LR, Ekbom P, Damm P, et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004; 27:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/13\">",
"      Herranz L, Saez-de-Ibarra L, Grande C, Pallardo LF. Non-glycemic-dependent reduction of late pregnancy A1C levels in women with type 1 diabetes. Diabetes Care 2007; 30:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/14\">",
"      Gandhi RA, Brown J, Simm A, et al. HbA1c during pregnancy: its relationship to meal related glycaemia and neonatal birth weight in patients with diabetes. Eur J Obstet Gynecol Reprod Biol 2008; 138:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/15\">",
"      Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/16\">",
"      Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000; 43:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/17\">",
"      Holmes VA, Young IS, Patterson CC, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011; 34:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/18\">",
"      Wyse LJ, Jones M, Mandel F. Relationship of glycosylated hemoglobin, fetal macrosomia, and birthweight macrosomia. Am J Perinatol 1994; 11:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/19\">",
"      Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004; 27:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/20\">",
"      Jovanovic L, Druzin M, Peterson CM. Effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetic women as compared with normal control subjects. Am J Med 1981; 71:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/21\">",
"      Mello G, Parretti E, Mecacci F, et al. What degree of maternal metabolic control in women with type 1 diabetes is associated with normal body size and proportions in full-term infants? Diabetes Care 2000; 23:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/22\">",
"      Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003; 189:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/23\">",
"      Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991; 164:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/24\">",
"      Ben-Haroush A, Yogev Y, Chen R, et al. The postprandial glucose profile in the diabetic pregnancy. Am J Obstet Gynecol 2004; 191:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/25\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/26\">",
"      Middleton P, Crowther CA, Simmonds L. Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev 2012; 8:CD008540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/27\">",
"      ter Braak EW, Evers IM, Willem Erkelens D, Visser GH. Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences. Diabetes Metab Res Rev 2002; 18:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/28\">",
"      Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/29\">",
"      Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/30\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/31\">",
"      Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetes mellitus--how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989; 161:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/32\">",
"      Whiteman VE, Homko CJ, Reece EA. Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Obstet Gynecol Clin North Am 1996; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     Harris J, Benedict F. A biometric study of basal metabolism in man. Washington DC. Carnegie Institute of Washington 1919.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/34\">",
"      Mifflin MD, St Jeor ST, Hill LA, et al. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990; 51:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/35\">",
"      Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     Weight Gain During Pregnancy: Reexamining the Guidelines. In: Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines, Rasmussen KM, Yaktine AL.  (Eds), National Academies Press (US), Washington DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/37\">",
"      Hillier TA, Pedula KL, Vesco KK, et al. Excess gestational weight gain: modifying fetal macrosomia risk associated with maternal glucose. Obstet Gynecol 2008; 112:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/38\">",
"      Mestman JH. Outcome of diabetes screening in pregnancy and perinatal morbidity in infants of mothers with mild impairment in glucose tolerance. Diabetes Care 1980; 3:447.",
"     </a>",
"    </li>",
"    <li>",
"     American Diabetes Association. Prepregnancy counseling and management of women with preexisting diabetes or previous gestational diabetes. In: Medical management of pregnancy complicated by diabetes, 3rd ed, ADA, Alexandria (VA) 2000. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/40\">",
"      Cousins L, Rigg L, Hollingsworth D, et al. The 24-hour excursion and diurnal rhythm of glucose, insulin, and C-peptide in normal pregnancy. Am J Obstet Gynecol 1980; 136:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/41\">",
"      Langer O, Anyaegbunam A, Brustman L, et al. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol 1988; 159:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/42\">",
"      Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/43\">",
"      Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 2005; 22:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/44\">",
"      Hod M, Damm P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198:186.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/45\">",
"      Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/46\">",
"      Bhattacharyya A, Brown S, Hughes S, Vice PA. Insulin lispro and regular insulin in pregnancy. QJM 2001; 94:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/47\">",
"      Lepercq J, Lin J, Hall GC, et al. Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Obstet Gynecol Int 2012; 2012:649070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/48\">",
"      Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized controlled trial comparing insulin determir with NPH insulin in 310 pregnant women with type 1 diabetes mellitus. Diabetes Care 2012; :in press.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/49\">",
"      Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001; 24:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/50\">",
"      Steel JM, Johnstone FD, Hume R, Mao JH. Insulin requirements during pregnancy in women with type I diabetes. Obstet Gynecol 1994; 83:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/51\">",
"      Garc&iacute;a-Patterson A, Gich I, Amini SB, et al. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 2010; 53:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/52\">",
"      McManus RM, Ryan EA. Insulin requirements in insulin-dependent and insulin-requiring GDM women during final month of pregnancy. Diabetes Care 1992; 15:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/53\">",
"      Weiss PA, Hofmann H. Intensified conventional insulin therapy for the pregnant diabetic patient. Obstet Gynecol 1984; 64:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/54\">",
"      Fuglsang J, Lauszus F, Flyvbjerg A, Ovesen P. Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes. J Clin Endocrinol Metab 2003; 88:4355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/55\">",
"      Oka R, Iura T, Miyamoto S. Large decreases in insulin requirement occurred repeatedly in two pregnancies in a type 1 diabetic woman. Acta Diabetol 2006; 43:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/56\">",
"      Spellacy WN, Buhi WC, Birk SA, McCreary SA. Distribution of human placental lactogen in the last half of normal and complicated pregnancies. Am J Obstet Gynecol 1974; 120:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/57\">",
"      Carl J, Christensen M, Mathiesen O. Human placental lactogen (hPL) model for the normal pregnancy. Placenta 1991; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/58\">",
"      Olszewski J, Szczurowicz A, W&oacute;jcikowski C. [Changes in levels of human placenta lactogen (hPL), progesterone, and estriol in blood serum and estrogens in urine during gestational diabetes mellitus]. Ginekol Pol 1995; 66:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/59\">",
"      Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990; 301:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/60\">",
"      Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004; 70:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/61\">",
"      Coustan DR, Reece EA, Sherwin RS, et al. A randomized clinical trial of the insulin pump vs intensive conventional therapy in diabetic pregnancies. JAMA 1986; 255:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/62\">",
"      Rudolf MC, Coustan DR, Sherwin RS, et al. Efficacy of the insulin pump in the home treatment of pregnant diabetics. Diabetes 1981; 30:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/63\">",
"      Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/64\">",
"      Roeder HA, Moore TR, Ramos GA. Insulin pump dosing across gestation in women with well-controlled type 1 diabetes mellitus. Am J Obstet Gynecol 2012; 207:324.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/65\">",
"      Jovanovic-Peterson L, Peterson, CM. Planting the pump. Diabetes Prof 1990; Spring: 23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/66\">",
"      Homko CJ, Sivan E, Reece AE. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? Treat Endocrinol 2004; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/67\">",
"      Kahn BF, Davies JK, Lynch AM, et al. Predictors of glyburide failure in the treatment of gestational diabetes. Obstet Gynecol 2006; 107:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/68\">",
"      Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/69\">",
"      Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/70\">",
"      Notelowitz, M. Sulfonylurea therapy in the treatment of the pregnanct diabetic. S A Med J 1971; 45:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/71\">",
"      Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343:1134.",
"     </a>",
"    </li>",
"    <li>",
"     Chmait, R, Dinise, T, Daneshmand, S, et al. Prospective cohort study to establish predictors of glyburide success in gestational diabetes. Am J Obstet Gynecol 2001; 185 (abstract).",
"    </li>",
"    <li>",
"     Kitzmiller, J. Limited efficacy of glyburide for glycemic control. Am J Obstet Gynecol 2001; 185 (abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/74\">",
"      Towner D, Kjos SL, Leung B, et al. Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 1995; 18:1446.",
"     </a>",
"    </li>",
"    <li>",
"     Langer, O, Conway, D, Berkus, M, et al. There is no association between hypoglycemic use and fetal anomalies. Am J Obstet Gynecol 1999; 180 (abstract).",
"    </li>",
"    <li>",
"     Koren, G. NIH/FDA Toxicology in Pregnancy Conference, Toronto, Canada, December 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/77\">",
"      Jacobson GF, Ramos GA, Ching JY, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005; 193:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/78\">",
"      Koren G. Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol 2001; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/79\">",
"      Hellmuth E, Damm P, M&oslash;lsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/80\">",
"      Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006; 86:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/81\">",
"      Guideline Development Group. Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ 2008; 336:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/82\">",
"      Garcia-Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet 2003; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/83\">",
"      Kemball ML, McIver C, Milner RD, et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970; 45:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/84\">",
"      Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 1968; 42:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/85\">",
"      Heerwagen MJ, Miller MR, Barbour LA, Friedman JE. Maternal obesity and fetal metabolic programming: a fertile epigenetic soil. Am J Physiol Regul Integr Comp Physiol 2010; 299:R711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/86\">",
"      ACOG Committee Obstetric Practice. ACOG Committee opinion. Number 267, January 2002: exercise during pregnancy and the postpartum period. Obstet Gynecol 2002; 99:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/87\">",
"      American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004; 27 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/19/20794/abstract/88\">",
"      Sigal RJ, Kenny GP, Wasserman DH, et al. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1433.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4802 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20794=[""].join("\n");
var outline_f20_19_20794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSING GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glycated hemoglobin (A1C)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21818703\">",
"      - Physiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21818696\">",
"      - Measurement and target A1C level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3995393\">",
"      - Self-monitoring of blood glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Target blood glucose values",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Deleterious effects of strict glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19751990\">",
"      Monitoring urine ketones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEDICAL NUTRITION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19752084\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Calorie requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19752207\">",
"      Caloric composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Calorie distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19752255\">",
"      Supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21821269\">",
"      Non-caloric sweeteners",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19752326\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H734996097\">",
"      - Type of insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H734996107\">",
"      - Insulin requirements across gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3995472\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19752455\">",
"      - Method of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral anti-hyperglycemic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ROLE OF EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTRAPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8374866\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4802|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/32/29197\" title=\"figure 1\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/50/19244\" title=\"table 1\">",
"      IOM weight and weight gain recommendations for pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/23/28027\" title=\"table 3\">",
"      Pharmacokinetics of insulin used in pregnant women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2519?source=related_link\">",
"      Intrapartum and postpartum management of insulin and blood glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_19_20795="Outcome surveil IA dysgerminoma";
var content_f20_19_20795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcomes of surveillance for stage IA ovarian dysgerminoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Author, year",
"      </td>",
"      <td class=\"subtitle1\">",
"       Progression free survival/total (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Overall survival/total (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asadourian, LA; 1969",
"      </td>",
"      <td>",
"       46/57 (80)",
"      </td>",
"      <td>",
"       52/57 (91)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Krepart, G; 1978",
"      </td>",
"      <td>",
"       5/5 (100)",
"      </td>",
"      <td>",
"       5/5 (100)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gordon, A; 1981",
"      </td>",
"      <td>",
"       58/72 (80)",
"      </td>",
"      <td>",
"       68/72 (95) (5-year)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Buskirk, SJ; 1987",
"      </td>",
"      <td>",
"       12/16 (75)",
"      </td>",
"      <td>",
"       16/16 (100) (5-year)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LaPolla, JP; 1987",
"      </td>",
"      <td>",
"       7/7 (100)",
"      </td>",
"      <td>",
"       7/7 (100)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dark, GG; 1997",
"      </td>",
"      <td>",
"       6/9 (66)",
"      </td>",
"      <td>",
"       9/9 (100)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vicus, D; 2010",
"      </td>",
"      <td>",
"       18/23 (78)",
"      </td>",
"      <td>",
"       23/23 (100)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20795=[""].join("\n");
var outline_f20_19_20795=null;
var title_f20_19_20796="Meningioma subtypes";
var content_f20_19_20796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meningioma subtypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        WHO grade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Meningiomas with low risk of recurrence or aggressive growth:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningothelial",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibrous (fibroblastic)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transitional (mixed)",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psammomatous",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiomatous",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microcystic",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Secretory",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphoplasmacyte-rich",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metaplastic",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Meningiomas with greater likelihood of recurrence and/or aggressive behavior:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clear cell (intracranial)",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chordoid",
"       </td>",
"       <td>",
"        II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhabdoid",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papillary",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic (malignant)",
"       </td>",
"       <td>",
"        III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningiomas of any subtype or grade with high proliferative index and/or brain invasion",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perry, A, Louis, DN, Scheithauer, BW, et al. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System, Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK (Eds), IARC Press, Lyon 2007. p. 164.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20796=[""].join("\n");
var outline_f20_19_20796=null;
var title_f20_19_20797="The effect of cadmium exposure on renal function";
var content_f20_19_20797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The effect of cadmium exposure on renal function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glomerular filtration rate (GFR, in percent of reference age adjusted values) as a function of blood cadmium in workers previously exposed to cadmium. There is a strong relation between increasing dose, as measured by blood cadmium, and decreasing GFR.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jarup, L, Persson, B, Elinder, CG,. Occup Environ Health 1995; 52:818.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20797=[""].join("\n");
var outline_f20_19_20797=null;
var title_f20_19_20798="Frequency of aneuploidy in congenital heart defects";
var content_f20_19_20798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Data expressed as overall rate of aneuploidy (percent) for individual congenital cardiac defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cardiac anomaly",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall aneuploid rate percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        T 21 percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        T 18 percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        T 13 percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        45X0 percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        22q11 deletion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AVSD",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VSD",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        10-17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TOF",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        6-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CoA",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CAT",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IAAb",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        17-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APVS",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLHS",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DORV",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitral atresia",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        UVH",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PS/PA + IVS",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid atresia",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TVD",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic stenosis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ASD",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGA",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        cTGA",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumours",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiomyopathy",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiosplenic syndromes",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DIV",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AVSD: atrioventricular septal defect; VSD: ventricular septal defect; TOF: tetralogy of Fallot; CoA: coarctation of the aorta; CAT: common arterial trunk; APVS: absent pulmonary valve syndrome; HLHS: hypoplastic left heart syndrome; DORV: double outlet right ventricle; UVH: univentricular heart; PS/PA + IVS: pulmonary stenosis/pulmonary atresia with intact ventricular septum; TVD: tricuspid valve dysplasia; ASD: atrial septal defect; TGA: transposition of the great arteries; cTGA: corrected transposition of the great arteries; DIV: double inlet ventricle; IAAb: interrupted aortic arch type B.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from studies by Allan et al. (Allan et al., 1994), Paladinin et al. (Paladini et al., 2002), Boldt et al. (Boldt et al., 2002) and Tennstedt et al. (Tennstedt et al., 1999). The incidence of individual types of aneuploidy as a percentage of the total number of aneuploid fetuses are adapted from Paladini et al. (Paladini, et al., 2002), Boldt et al. (Boldt et al., 2002) and Tennstedt et al. (Tennstedt et al., 1999). Incidence of 22q11 deletion adapted from Marino et al. (Marino et al., 2001), Yamagishi et al., 2000), McElhinney et al. (McHElhinney et al., 2003), Lewin et al., 1997) and Ryan et al. (Ryan et al., 1997).",
"     <br>",
"      Reproduced with permission from: Wimalasundera, RC, Gardiner, HM. Congenital heart disease and aneuploidy. Prenat Diagn 2004; 24:1116. Copyright &copy; 2004 John Wiley &amp;Sons.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20798=[""].join("\n");
var outline_f20_19_20798=null;
var title_f20_19_20799="Glaucomatous optic disc";
var content_f20_19_20799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glaucomatous optic disc cupping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the inferior elongation of the cup. Vertical cup:disc ratio is 0.8, horizontal cup:disc ratio is 0.5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_19_20799=[""].join("\n");
var outline_f20_19_20799=null;
